WO2012029899A1 - Package - Google Patents
Package Download PDFInfo
- Publication number
- WO2012029899A1 WO2012029899A1 PCT/JP2011/069881 JP2011069881W WO2012029899A1 WO 2012029899 A1 WO2012029899 A1 WO 2012029899A1 JP 2011069881 W JP2011069881 W JP 2011069881W WO 2012029899 A1 WO2012029899 A1 WO 2012029899A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- package
- layer
- solid preparation
- container
- aluminum foil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/325—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
- B65D75/326—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming one compartment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
- B65D81/267—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants the absorber being in sheet form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D2585/00—Containers, packaging elements or packages specially adapted for particular articles or materials
- B65D2585/56—Containers, packaging elements or packages specially adapted for particular articles or materials for medicinal tablets or pills
Definitions
- the present invention relates to a package, and more particularly to a package having high hygroscopicity and gas adsorbability and high moldability.
- a press-through pack (PTP) package has been widely used for packaging pharmaceutical products.
- the PTP package is a package in a form that is sealed with a lid material that is easy to tear after the packaged material is accommodated in the container, and the lid material is torn by pressing from the container side toward the lid material side. Is taken out. Since such a PTP package is excellent in airtightness, handleability, portability, and productivity and can save resources, it is expected that the future demand will be further increased as a package for pharmaceutical products.
- the material on the container side of the PTP package it is common to use a single layer of a polypropylene sheet or a polyvinyl chloride sheet, or a laminate composed of a plurality of materials in which a film or the like is laminated on an aluminum foil. Moreover, as the material on the lid member side, an aluminum foil coated with a resin is often used.
- Patent Document 1 proposes a PTP package having a configuration in which a container using a highly moisture-proof aluminum foil and a lid material are bonded together.
- the aluminum foil constituting the container is provided with a polyamide-based resin layer that is stretched on one side, and a thermal adhesive layer is provided on the other side.
- it can be set as the moisture-proof PTP package by heat-sealing the aluminum foil of the structure similar to the aluminum foil which comprises the cover material containing an aluminum foil, or a container, and a container.
- Patent Document 2 a technique is proposed in which a moisture absorbing layer is provided in a container of a PTP package and a drying function is imparted to the PTP package. Since the PTP package provided with a drying function can cause the drying function to act on the package, it can be stored well even if the package is hydrolyzable or highly hygroscopic. can do.
- Patent Document 1 aluminum having high moisture resistance is used as a material constituting the container, and the lid member is also made of aluminum. And by heat-sealing the container and the lid material, it is possible to provide a PTP packaging body having moisture resistance.
- the portion in which the package body is enclosed There was a problem that the water remaining inside the storage part) could not be removed, and the quality of the solid preparation was impaired. Therefore, a PTP package having a capability of absorbing moisture as well as moisture is desired. Further, depending on the package, there is a property that the decomposition is further promoted by the gas generated at the time of decomposition. Therefore, a PTP package capable of adsorbing not only moisture but also gas has been desired.
- a PTP packaging in which a drying function is provided to the packaged body and the inside (container) in which the packaged body is sealed is provided. It can be a body.
- the PTP package (blister package) disclosed in Patent Document 2 creates a film by bonding a moisture-absorbing layer to a moisture-proof barrier layer, and forms a PTP package by using this film. At this time, the film provided with the barrier layer and the moisture absorbing layer is formed with an accommodation portion for accommodating an object to be packaged in a heat-softened state.
- An object of the present invention is to provide a package having a hygroscopic property and a gas adsorbing property and having good moldability.
- another object of the present invention is to provide a package body having a hygroscopic property and a gas adsorbing property and having an appropriate rigidity.
- the object is to provide a package containing a solid preparation containing solifenacin succinate or 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexaneacetic acid according to the package according to the present invention.
- the package body is provided with a container sheet in which a concave container for containing the solid preparation is formed, and a lid sheet with airtightness for sealing the solid preparation,
- the container sheet is composed of a packaging film in which an adsorption layer, at least one base layer composed of a resin, an aluminum foil, and a barrier layer are laminated, and the adsorption layer includes the base layer and the base layer. This is solved by being laminated and disposed on the side where the solid preparation is accommodated, and containing at least zeolite.
- the container sheet constituting the package of the present invention includes the adsorption layer containing zeolite on the side where the solid preparation is accommodated, water in the accommodating portion and other molecules (gas molecules) Can be adsorbed. Furthermore, since the container sheet is provided with a highly moisture-proof aluminum foil, the moisture resistance of the package is dramatically improved by being combined with the adsorption layer. Moreover, since the packaging body film which comprises the container sheet
- the solid preparation contained in the package is sufficiently protected, and when the PTP package is used, the solid preparation can be taken out with an appropriate external force.
- 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexaneacetic acid is a hydrolyzable substance, and generates acetaldehyde that causes odor by the hydrolysis reaction.
- the solid preparation containing the compound is easily colored by moisture absorption. Accordingly, the package is required to have high moisture absorption and gas adsorption.
- the package of the present invention can prevent generation of unpleasant odors and coloring of solid preparations by adsorbing water, acetaldehyde and the like by the adsorption layer. As a result, the preservation state of the solid preparation containing the compound can be favorably maintained.
- the base material layer is preferably made of a polyamide resin or a polyvinyl chloride resin.
- a polyamide resin or a polyvinyl chloride resin By using the above material as the base material layer, an appropriate rigidity can be imparted to the packaging film. As a result, when the container sheet constituting the package is formed, it can be easily formed by press working.
- the ratio of the height of the housing portion to the diameter of the housing portion is formed with 0.335 as an upper limit.
- the pinhole occurrence rate increases as the film is stretched. Therefore, when designing a storage part to be molded by press processing according to the shape or size of a pharmaceutical preparation such as a tablet or capsule to be stored, an appropriate frontage of the storage part is used to ensure the required height.
- the ratio of the height of the accommodating portion to the diameter of the accommodating portion (the height of the accommodating portion / the diameter of the accommodating portion) is regulated to be equal to or less than a target value unique to each film.
- the ratio of the height of the storage portion and the diameter of the storage portion equal to or less than the above numerical value, the occurrence of pinholes can be prevented when the container sheet of the package is formed.
- the larger the ratio of the height of the housing portion to the diameter of the housing portion the larger the boundary portion between the top surface of the housing portion and the side surface of the housing portion (shoulder R Part) vicinity, a pinhole arises in the aluminum foil in a packaging body film.
- the container sheet is formed by press working that does not heat the packaging film
- the ratio of the height of the container to the diameter of the container is larger than the above value
- the probability of occurrence of pinholes in the container increases.
- the value is less than or equal to the above value, the probability of occurrence of pinholes can be made substantially zero. Therefore, when the packaging body film is pressed, a pinhole is unlikely to be generated in the housing portion, so that the packaging body having excellent moisture resistance can be obtained.
- the lid sheet is provided with an aluminum foil.
- the moisture resistance between the solid formulation container formed on the container sheet and the lid sheet can be improved.
- water and gas molecules in the storage portion are adsorbed by the adsorption layer provided in the storage portion formed in the container sheet, so that moisture resistance is improved.
- the lid sheet is made of aluminum foil, it is preferable that the PTP package is easily broken by an external force applied from the container sheet side, and as a result, the solid preparation in the container can be easily taken out.
- the effective pore diameter of the zeolite is preferably 3 mm or more. Since zeolite has a high adsorption rate, it can adsorb moisture quickly.
- Molecular sieve which is an example of zeolite, is a porous granular material used to separate materials according to the difference in molecular size, and has a structure with uniform pores. It acts as a kind of sieve by adsorbing molecules. In the present invention, when a molecular sieve is used, the adsorption port diameter is preferably 0.3 nm to 1 nm.
- molecular sieves having pore sizes of 0.3 nm, 0.4 nm, 0.5 nm, and 1 nm are referred to as molecular sieve 3A, molecular sieve 4A, molecular sieve 5A, and molecular sieve 13X, respectively.
- molecular sieve 3A or molecular sieve 4A is used as a suitable desiccant.
- the average particle diameter of the molecular sieve is, for example, about 10 ⁇ m.
- the substance adsorbed by the zeolite depends on the effective pore size of the zeolite.
- the effective pore size of the zeolite is less than 4 mm, water can be adsorbed but relatively large molecules such as carbon dioxide and acetaldehyde cannot be adsorbed sufficiently.
- the effective pore diameter of the zeolite is 4 mm or more, relatively large molecules such as water, carbon dioxide, acetaldehyde, hydrogen sulfide, ethane, and ethanol can be adsorbed. Therefore, when only water affects the storage state of the solid preparation, the solid preparation can be stored in a good state when the effective pore diameter of the zeolite is 3 mm or more.
- the effective pore size of the zeolite is 4 mm or more, substances that emit odors such as hydrogen sulfide and substances that may affect the storage state of solid preparations such as ethanol are also adsorbed by the adsorption layer, which is good.
- the solid preparation can be stored in a safe storage state.
- the adsorption layer is provided in the packaging body film constituting the container sheet, and the base layer and the aluminum foil are further provided thereon. Therefore, the package is not only highly moisture-proof due to the aluminum foil, but also the moisture absorption is improved by adsorbing water and gas molecules in the container of the solid preparation by the adsorption layer, and appropriate rigidity is imparted by the base material layer. Is done. As a result of imparting appropriate rigidity, the package of the present invention can be easily processed by pressing without heating, and the moldability is dramatically improved. And the yield improves with the improvement of a moldability. Furthermore, as a result of imparting appropriate rigidity, the package of the present invention can improve the storage state of the solid preparation.
- the ratio of the height of the storage portion to the diameter of the storage portion that stores the solid preparation is a predetermined height or less, it is possible to prevent the occurrence of pinholes particularly in the vicinity of the storage portion. Furthermore, moisture resistance is further improved by providing the lid sheet with an aluminum foil. Furthermore, by setting the effective pore diameter of the zeolite contained in the adsorption layer to a predetermined value or more, not only water but also other gas molecules can be adsorbed. And the solid preparation can be stored in a good storage state.
- P packaging body F1, F2 packaging body film 1 adsorption layer 2 base material layer 2a main base material layer 2b sub base material layer 3 aluminum foil 4 barrier layer 5 container 6 container sheet 7 lid material sheet 8 solid preparation
- FIG. 1 is a schematic cross-sectional view of a packaging body film
- FIG. 2 is a schematic cross-sectional view of the packaging body
- FIGS. 3 to 6 are Embodiment 1 of the present invention.
- FIG. 7 is a graph of color difference measurement results in Comparative Examples 1 and 2
- FIG. 7 is a graph of elution degree in Example 1 of the present invention
- Comparative Examples 1 and 2 and
- FIG. 8 is related to another embodiment of the present invention. It is a schematic sectional drawing of a package body film.
- the packaging body film F1 As shown in FIG. 1, the packaging body film F1 according to one embodiment of the present invention is constituted by laminating an adsorption layer 1, at least one base material layer 2, an aluminum foil 3 and a barrier layer 4 in this order. Has been. A packaged body is disposed on the lower side of FIG.
- the adsorbing layer 1 is preferably made of a resin and zeolite formed into a film or sheet by an inflation method, a T-die method, co-extrusion or the like.
- the thickness of the adsorption layer 1 is preferably 30 to 100 ⁇ m in order to adsorb a sufficient amount of moisture and gas.
- Examples of the resin material constituting the adsorption layer 1 include LDPE (low density polyethylene), LLDPE (linear low density polyethylene), PP (polypropylene), chlorinated polypropylene, saturated polyester, EAA (ethylene-acrylic acid copolymer). ), EMAA (ethylene-methacrylic acid copolymer), EEA (ethylene-ethyl acrylate copolymer), EMA (ethylene-methyl acrylate copolymer), ionomer, carboxylic acid modified polyethylene, carboxylic acid modified polypropylene, carboxylic acid modified At least one selected from EVA, PVC (polyvinyl chloride), polystyrene and the like, or a combination thereof can be used.
- EVA low density polyethylene
- LLDPE linear low density polyethylene
- PP polypropylene
- chlorinated polypropylene saturated polyester
- EAA ethylene-acrylic acid copolymer
- EMAA ethylene-methacrylic acid copolymer
- the material for the skin layer is not particularly limited as long as it (1) prevents the zeolite-containing layer from being exposed on the surface and directly contacts the preparation, or (2) improves the laminating property.
- Examples of the material for the skin layer include LDPE (low density polyethylene), LLDPE (linear low density polyethylene), PP (polypropylene), chlorinated polypropylene, saturated polyester, EAA (ethylene-acrylic acid copolymer), and EMAA.
- Ethylene-methacrylic acid copolymer EEA (ethylene-ethyl acrylate copolymer), EMA (ethylene-methyl acrylate copolymer), ionomer, carboxylic acid-modified polyethylene, carboxylic acid-modified polypropylene, carboxylic acid-modified EVA, PVC (Polyvinyl chloride), at least one selected from polystyrene and the like, or a combination thereof can be used.
- the zeolite constituting the adsorption layer 1 contains a molecular sieve, and the molecular sieve preferably has an effective pore diameter of about 3 to 10 mm.
- the molecular sieve selects the effective pore diameter according to the size of the object to be adsorbed. In particular, when the effective pore size is 4 mm or more, not only water but also gas molecules such as carbon dioxide, acetaldehyde, hydrogen sulfide, ethane, and ethanol can be adsorbed.
- a substance that causes odors such as acetaldehyde and hydrogen sulfide is also preferred because it is adsorbed by the adsorption layer 1.
- artificial zeolite is obtained by forming a substance similar in nature to natural zeolite from various substances by an industrial method. Therefore, the adsorptivity and ion exchange properties are improved. Therefore, the zeolite material constituting the adsorption layer 1 may be appropriately selected according to the substance to be adsorbed.
- the base material layer 2 is a layer made of a resin bonded to the adsorption layer 1 and mainly imparts appropriate rigidity and moldability to the packaging body film F1.
- a material of the base material layer 2 at least one selected from polyvinyl chloride, polypropylene, polyvinylidene chloride, polyamide such as nylon (registered trademark), and the like, or a combination thereof can be used.
- polyamides such as nylon (registered trademark) and PVC (polyvinyl chloride) are preferable, and PVC (polyvinyl chloride) having an appropriate elongation property is particularly preferable.
- the thickness of the base material layer 2 is preferably 15 to 25 ⁇ m in order to ensure the rigidity of the packaging body film F1 and to maintain good moldability.
- the aluminum foil 3 may be a pure aluminum foil or an aluminum alloy foil. Further, a pure aluminum foil coated with a resin such as PP (polypropylene) may be used. In addition, the thickness of the aluminum foil 3 is preferably 30 to 60 ⁇ m in order to maintain good moldability, maintain moisture resistance and light-shielding properties of the container, and provide appropriate rigidity and moldability.
- the barrier layer 4 is formed from a film-like material that can be sealed.
- the material constituting the barrier layer 4 include HDPE (high density polyethylene), MDPE (medium density polyethylene), LDPE (low density polyethylene), polyvinylidene chloride, polychlorotrifluoroethylene, PP (polypropylene), polyethylene terephthalate, And at least one selected from polyamide such as nylon (registered trademark), etc., or a combination thereof. Among these, it is preferable to select polyamide such as nylon (registered trademark) because the moldability is improved.
- the barrier layer 4 is preferably 5 to 30 ⁇ m in order to maintain sufficient hermeticity and appropriate moldability.
- an adhesive layer may be provided between the adsorption layer 1, the base material layer 2, the aluminum foil 3, and the barrier layer 4, respectively.
- the adhesive layer include urethane-based adhesive, HDPE (high density polyethylene), MDPE (medium density polyethylene), LDPE (low density polyethylene), polypropylene, chlorinated polypropylene, saturated polyester, EAA (ethylene- Acrylic acid copolymer), EMAA (ethylene-methacrylic acid copolymer), EEA (ethylene-ethyl acrylate copolymer), EMAC (ethylene-methyl acrylate copolymer), ionomer, carboxylic acid-modified polyethylene, carboxylic acid-modified At least one selected from polypropylene, carboxylic acid-modified EVA, PVC (polyvinyl chloride), polystyrene and the like, or a combination thereof can be used.
- the thickness of the adhesive layer (not shown) is preferably about 10 ⁇ m.
- each layer of the said adsorption layer 1, the base material layer 2, the aluminum foil 3, and the barrier layer 4 can be bonded together by a well-known method, and methods, such as extrusion lamination, dry lamination, wet lamination, thermal lamination, sand lamination, etc. Can be pasted together.
- the packaging body film F1 composed of the adsorption layer 1, the base material layer 2, the aluminum foil 3, and the barrier layer 4 only needs to have appropriate rigidity to form the packaging body P described later. Accordingly, the total thickness of each layer, that is, the thickness of the packaging body film F1 is preferably about 120 to 200 ⁇ m.
- the packaging body P As shown in FIG. 2, the packaging body P according to an embodiment of the present invention is formed by a container sheet 6 formed by the packaging film F1 and a lid sheet 7 having airtightness.
- the solid preparation 8 is packaged inside the container 5. 2 exaggerates the thickness of the container sheet 6 for the sake of explanation.
- the container sheet 6 is formed of a package film F1 in which an adsorption layer 1, at least one base layer 2, an aluminum foil 3, and a barrier layer 4 are laminated. And the container sheet
- seat 6 is formed with the one or more concave accommodating parts 5 which accommodate the solid formulation 8 using the packaging body film F1.
- the container sheet 6 has a configuration in which the adsorption layer 1 is disposed on the surface on the side where the solid preparation 8 is accommodated, as shown in FIG.
- the adsorption layer 1 is disposed on the surface on the side where the solid preparation 8 is accommodated, as shown in FIG.
- the container sheet 6 having the above-described configuration has one or more accommodating portions 5 formed on the packaging film F1 by a technique such as press molding.
- the shape of the accommodating part 5 is suitably designed depending on the shape of the solid preparation 8 accommodated inside.
- the method of press molding is not particularly limited, a known method such as stretch forming or deep drawing is used.
- the lid material sheet 7 is in close contact with the surface of the container sheet 6 on which the adsorption layer 1 is provided, and seals the inside of the storage unit 5 in which the solid preparation 8 is stored. If the adhesion between the container sheet 6 and the lid sheet 7 is low, a heat-sealable resin layer (not shown) may be provided on the surface of the adsorption layer 1 facing the lid sheet 7. good. As a material for the heat-sealable resin layer, a material equivalent to the adhesive layer (not shown) can be used.
- the lid material sheet 7 is formed from a film-like material that can be sealed and has a property of preventing the inflow and outflow of gas such as water vapor.
- the material constituting the lid sheet 7 include aluminum, high density polyethylene, medium density polyethylene, low density polyethylene, polyvinylidene chloride, polychlorotrifluoroethylene, and polyamide such as polypropylene and nylon (registered trademark). At least one selected, or a combination thereof can be used. Among these, aluminum is preferable because moisture resistance and light shielding properties of the container are improved. When aluminum is used, it is preferable that an adhesive be applied to the surface facing the container sheet 6.
- ethylene-vinyl acetate copolymer polyvinylidene chloride, vinyl chloride-vinyl acetate copolymer, chlorinated polypropylene, and the like can be used.
- Aluminum may be either pure aluminum or an aluminum alloy.
- Adsorption layer 1 LLDPE (both LLDPE (made by Tosoh Corporation, trade name: Petrocene 202, thickness: 50 ⁇ m)) containing LDPE (made by Union Showa Co., Ltd., trade name: molecular sieve 4A, effective pore size: 4 mm) Made of Prime Polymer Co., Ltd., trade name: Evolue (registered trademark) SP2520) skin layer 2 type 3 layer base material layer 2: PA (polyamide resin) (made by Kojin Co., Ltd., trade name: Bonil W) , Thickness: 15 ⁇ m)
- Aluminum foil 3 Alloy aluminum foil (manufactured by Toyo Aluminum Co., Ltd., trade name: super foil, thickness: 40 ⁇ m)
- Barrier layer 4 PA (polyamide resin) (manufactured by Kojin Co., Ltd., trade name: Bonile W, thickness: 15 ⁇ m)
- Adsorption layer 1 LLDPE (on both sides of the LDPE (product name: Petrocene 202, thickness: 50 ⁇ m) layer containing zeolite (manufactured by Union Showa Co., Ltd., trade name: Molecular sieve 4A, effective pore size: 4 mm)) Made of Prime Polymer Co., Ltd., trade name: Evolue (registered trademark) SP2520) skin layer laminated, 2 types and 3 layers
- Base material layer 2 PVC (polyvinyl chloride) (thickness: 60 ⁇ m)
- Aluminum foil 3 Alloy aluminum foil (manufactured by Sumi Light Aluminum Foil Co., Ltd., trade name: BESP AII, thickness: 40 ⁇ m)
- Barrier layer 4 PA (polyamide resin) (manufactured by Toyobo Co., Ltd., trade name: Harden N2102, thickness: 15 ⁇ m)
- Table 2 shows a case in which a plurality of accommodating portions 5 are formed at different heights, and the light transmittance in each accommodating portion 5 is visually confirmed.
- the pockets where light transmission was confirmed were counted as having pinholes, and the pinhole generation rate relative to the whole was shown.
- the pocket diameter of the mold used for molding is 15 mm.
- Measured pinhole occurrence rate of each accommodating part 5 was found to be 0% when the height of the accommodating part 5 was 5.032 mm or less. Therefore, from the above test results, when the diameter of the accommodating part 5 is 15 mm, it is preferable that the height of the accommodating part 5 is 5.032 mm or less because no pinhole is observed.
- the “height” of the container 5 is the distance from the flat surface of the barrier layer 4 of the container sheet 6 (that is, the surface where the container 5 is not formed) to the uppermost surface (top surface) of the pocket ( It refers to H) in FIG. Further, the “diameter (pocket diameter) of the accommodating portion 5” refers to the inner diameter of the opening of the accommodating portion 5 (that is, L in FIG. 2).
- the opening part of the accommodating part 5 does not necessarily need to be a perfect circle.
- the “diameter of the housing part 5 (pocket diameter)” refers to the inner diameter in the longitudinal direction.
- the packaging body film F1 including one or more kinds of the base material layers 2 is suitable without generating cracks and pinholes when the packaging body P is formed.
- the diameter of the accommodating part 5 was 15 mm
- the package P that does not include the base material layer 2 was molded, cracks occurred in the vicinity of the top surface of the housing 5.
- the ratio of the height of the housing part 5 to the diameter of the housing part 5 is formed with an upper limit of 0.335 based on the test result.
- the height of the accommodating part 5 will not be specifically limited if it selects suitably by the shape or magnitude
- Adsorption layer 1 zeolite (made by Union Showa Co., Ltd., trade name: molecular sieve 4A, effective pore size: 4 mm) containing LDPE (made by Tosoh Corporation, trade name: Petrocene 202, thickness: 130 ⁇ m) on both sides of LLDPE ( Made of Prime Polymer Co., Ltd., trade name: Evolue (registered trademark) SP2520) skin layer 2 type 3 layer base material layer 2: PA (polyamide resin) (made by Kojin Co., Ltd., trade name: Bonil W) , Thickness: 15 ⁇ m)
- Aluminum foil 3 Alloy aluminum foil (manufactured by Toyo Aluminum Co., Ltd., trade name: super foil, thickness: 40 ⁇ m)
- Barrier layer 4 PA (polyamide resin) (manufactured by Kojin Co., Ltd., trade name: Bonile W, thickness: 15 ⁇ m)
- the package P of the present invention contains 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl], a drug containing a component that is hydrolyzed by moisture in the storage environment or moisture contained in the solid preparation 8. Particularly useful for drugs containing aminomethyl ⁇ -1-cyclohexaneacetic acid.
- the package P is applied to the solid preparation 8 containing 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexaneacetic acid will be described.
- the solid preparation 8 is a sustained-release oral drug comprising tablets, and has 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1 represented by the chemical formula (1) as an active ingredient.
- 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexaneacetic acid is a prodrug of gabapentin (chemical formula (2)) which is a ⁇ -aminobutyric acid (GABA) derivative.
- Symptoms for which gabapentin is prescribed and for which drugs containing gabapentin are effective include epilepsy, depression, anxiety, psychosis, cognition, schizophrenia, fainting, motor function decline, cranial disorders, neurodegenerative disorders, panic, Pain ⁇ especially neuropathic pain (eg postherpetic neuralgia), muscle pain, and skeletal pain ⁇ , restless leg syndrome, hot flashes, urinary incontinence, inflammatory disorders (ie arthropathy), insomnia, gastrointestinal disorders, alcohol / Cocaine poisoning, ethanol withdrawal syndrome, vulvar lesions, premature ejaculation, glutamatergic activity, etc.
- epilepsy depression, anxiety, psychosis, cognition, schizophrenia, fainting, motor function decline, cranial disorders, neurodegenerative disorders, panic, Pain ⁇ especially neuropathic pain (eg postherpetic neuralgia), muscle pain, and skeletal pain ⁇ , restless leg syndrome, hot flashes, urinary incontinence, inflammatory disorders (ie arthropathy
- the drug can be administered to patients as a preventive measure against the above diseases or disorders. Therefore, the drug is used for epilepsy, depression, anxiety, psychosis, fainting, decreased motor function, cranial disorder, neurodegenerative disorder, panic, pain (especially neuropathic pain and muscle pain, and skeletal pain), It can be administered as a preventive measure to patients with a tendency for inflammatory disorders (ie arthropathy), insomnia, gastrointestinal disorders, ethanol withdrawal syndrome, premature ejaculation, and vulvar lesions.
- the medicament can be used for the prevention of certain diseases or disorders and at the same time to treat other diseases or disorders (e.g. prevention of psychosis, treatment of gastrointestinal disorders, prevention of neuropathic pain, Treatment of ethanol withdrawal syndrome, etc.).
- diseases or disorders e.g. prevention of psychosis, treatment of gastrointestinal disorders, prevention of neuropathic pain, Treatment of ethanol withdrawal syndrome, etc.
- agents can be used in combination with other drugs, such as antiviral drugs, during early viral infections to inhibit or reduce events resulting from neurological disorders.
- Suitable dosage ranges for oral administration of gabapentin are usually about 100 mg / day to about 3600 mg / day and 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexane Acetic acid or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof can be adjusted to provide equimolar amounts of gabapentin.
- the dose range can be readily determined by methods known to those skilled in the art.
- the amount of 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexaneacetic acid in the solid formulation is about 50 mg to about 800 mg, in some embodiments about 100 mg to about 800 mg, and In some embodiments, it will be in the range of about 300 mg to about 700 mg.
- the dosage is orally administered 1 to 3 times per day. The dose is expected to be appropriately determined according to individual cases in consideration of symptoms, age, sex, and the like.
- 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexaneacetic acid is hydrolyzed in the presence of water to give 1 mol of water and 1- ⁇ [( ⁇ -isobutanoyloxy, respectively).
- 1 mol of acetaldehyde, carbon dioxide, gabapentin and isobutyl alcohol are generated from ethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexaneacetic acid, respectively.
- the solid preparation 8 includes 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexaneacetic acid as an active ingredient, and a release rate controlling polymer, excipient, and diluent as additives.
- Fluidizers, lubricants, thickening inhibitors, surfactants, buffers, dyes, wetting agents, emulsifiers, pH buffers, stabilizers, thickeners, disintegrants, and colorants One or two or more additives can be added in an appropriate amount.
- the release rate controlling polymer is a glyceryl ester such as glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, lauroyl macrogol glyceride, stearoyl macrogol glyceride, or any combination of the above.
- the release rate improving polymer is glyceryl behenate.
- Other fat and / or wax release rate improving polymers include lauryl alcohol, myristyl alcohol, stearyl alcohol, cetyl alcohol, cetostearyl alcohol, palmitoyl alcohol, ouricury wax, hydrogenated vegetable oil, candelilla wax, esparto wax, stearic acid, Includes paraffin wax, beeswax, glycowax, castor wax, and carnauba wax.
- Excipients include starch, sugar, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, glycerol, propylene glycol, water, ethanol and the like.
- Diluents can be added to increase the volume of the drug to make it practical for compression. Examples of useful diluents are dicalcium phosphate, dicalcium phosphate dihydride, calcium sulfate, tricalcium phosphate, lactose, cellulose containing microcrystalline cellulose, kaolin, mannitol, sodium chloride, dried starch, alpha starch, Compressible sugar, mannitol, and combinations of any of the above.
- the single diluent is selected from dicalcium phosphate and microcrystalline cellulose.
- the agent may include an amount of diluent that ranges from about 30 wt% to about 50 wt%, and in some embodiments from about 35 wt% to about 45 wt%.
- the agent comprises an amount of diluent that ranges from about 5 wt% to about 20 wt%, and in some embodiments from about 10 wt% to about 16 wt%. I can do it.
- a fluidizing agent is included in the drug of the present invention to reduce the adhesion effect during manufacture, film formation, and / or drying.
- useful fluidizing agents are talc, magnesium stearate, glyceryl monostearate, colloidal silicon dioxide, precipitated silicon dioxide, any combination of the above.
- the fluidizing agent is colloidal silicon dioxide.
- the medicament may comprise less than about 2% by weight fluidizing agent, and in certain embodiments, less than about 1% by weight fluidizing agent.
- Lubricants and thickening inhibitors can be included in the agents of the present invention to aid in processing.
- useful lubricants and / or thickening inhibitors are calcium stearate, glyceryl behenate, glyceryl monostearate, magnesium stearate, mineral oil, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulfate, dodecyl Sodium sulfate, stearic acid, talc, hydrogenated vegetable oil, zinc stearate, and any combination of the above.
- the lubricant is glyceryl monostearate.
- the lubricant is magnesium stearate.
- the medicament may comprise from about 1% to about 13% by weight, in some embodiments, from about 4% to about 10% by weight lubricants and / or thickening inhibitors.
- surfactants useful in the agents of the present invention include pharmaceutically acceptable anionic surfactants, cationic surfactants, amphoteric ⁇ amphiphilic / amphiphilic ⁇ surfactants. Agents, nonionic surfactants, polyethylene glycol esters or ethers, and combinations of any of the above. Suitable pharmaceutically acceptable anionic surfactants are monovalent alkyl carboxylates, acyl lactylates, alkyl ether carboxylates, N-acyl sarcosinates, polyvalent alkyl carbonates, N-acyl glutamates, fatty acid-polys.
- the solid preparation 8 of the present embodiment is formed of a shaped tablet, but may be a capsule.
- composition per tablet was as follows: 1- ⁇ [( ⁇ -isobutanoyloxyethoxy) carbonyl] aminomethyl ⁇ -1-cyclohexaneacetic acid 300 mg, calcium hydrogen phosphate 259.1 mg, glycerin fatty acid ester 30.05 mg, talc 40 0.0 mg, light anhydrous silicic acid 2.7 mg, sodium lauryl sulfate 12.0 mg, and magnesium stearate 11.15 mg.
- Example 1 The solid body 8 obtained in the above formulation example is sealed by adhering and sealing the container sheet 6 formed by the packaging film F1 having the following configuration and the lid sheet 7 made of aluminum. Obtained.
- seat 6 for containers of Example 1 is the same as that of Example 1 mentioned above, the description is abbreviate
- Adsorption layer 1 low density polyethylene containing calcium oxide (calcium oxide amount relative to polyethylene: 30 wt%) (thickness: 40 ⁇ m)
- Base material layer 2 EAA (ethylene-acrylic acid copolymer) (thickness: 10 ⁇ m)
- Aluminum foil 3 Pure aluminum foil (thickness: 45 ⁇ m)
- Barrier layer 4 Stretched polyamide resin (thickness: 25 ⁇ m)
- coloring means that a color other than white is exhibited in appearance.
- the following tests were performed using the package P of the solid preparation 8 obtained in Example 1 and Comparative Examples 1 and 2 as a sample.
- the solid preparation 8 stored in a cold place after production at a predetermined temperature was used as a control sample, and the samples of Example 1 and Comparative Examples 1 and 2 were 50 ° C., 40 ° C., 30 ° C., and 25 ° C., respectively (relative humidity). 75%) was used as a sample after storage.
- the solid preparation 8 packaged in each package P was taken out, and the appearance was evaluated by measuring the color difference ⁇ E between the control sample and the sample after storage with a color difference meter (CM-3500d, manufactured by Konica Minolta).
- FIG. 3 shows that when stored at 50 ° C., Example 1 has a lower degree of coloring of solid preparation 8 than Comparative Examples 1 and 2. Compared to Comparative Example 1 that does not include the adsorption layer 1, the color difference ⁇ E of Example 1 is about one third after 3 days, and the packaging P of Example 1 colored the solid preparation 8. Is greatly suppressed. Furthermore, it was shown that Example 1 can suppress coloring of the solid preparation 8 rather than the package P of Comparative Example 2 containing calcium oxide in the adsorption layer 1.
- Example 1 showed that the degree of coloring of the solid preparation 8 was smaller than that of Comparative Examples 1 and 2 even when stored at 40 ° C.
- ⁇ E showed a high value of about 32 after one month, but Comparative Example 2 containing calcium oxide in the adsorption layer 1 and Example 1 was about 1.
- ⁇ E of Example 1 was about 12, but ⁇ E of Comparative Example 2 was about 22, and the difference in ⁇ E was remarkable after long-term storage. It was. Therefore, it was shown by this color difference measurement that the package P of the present invention effectively suppresses coloring.
- FIG. 5 shows that Example 1 and Comparative Example 1 are slightly different when stored at 30 ° C., but ⁇ E is smaller in Example 1.
- ⁇ E is smaller in Example 1.
- the degree of coloring is extremely small, and it is confirmed that it is suitable for storage of the solid preparation 8 It was done.
- Example 1 when stored at 25 ° C., after 6 months, Example 1 shows that ⁇ E is held at a small value as compared with Comparative Example 2 in which calcium oxide is contained in the adsorption layer 1. ing. Even in the case of 25 ° C., it was confirmed that the degree of coloring remained small when 6 months passed.
- the packaging body P of Example 1 (the thickness of the adsorption layer 1 is 50 ⁇ m) was evaluated, but the packaging body P of Example 2 described above (however, the thickness of the adsorption layer 1 was set to 130 ⁇ m).
- the color difference measurement of the layer structure other than the adsorption layer 1 is the same as that of the above-described Example 2, the both showed substantially the same color difference ⁇ E.
- Test Example 4 Dissolution rate of orally disintegrating tablets
- the package P of Example 1 and Comparative Examples 1 and 2 the effect of the package P of the present invention on the orally disintegrating tablet containing a water-soluble drug component was evaluated.
- the description is abbreviate
- solid preparation 8 which is a 150 mg orally disintegrating tablet containing solifenacin succinate was produced.
- Orally disintegrating tablets are packaged by the package P of Example 1 and Comparative Examples 1 and 2 for 3 months (Example 1-1, Comparative Example 1-1, Comparative Example 2-1) and 6 months, respectively.
- Example 1-2, Comparative Example 1-2 Stored (storage conditions: 40 ° C., relative humidity 75%, dark place).
- FIG. 7 shows the degree of dissolution of the orally disintegrating tablet after a predetermined storage period (measured after 0, 30, 45 minutes). The dissolution test was carried out at 900 rpm with a paddle method using 900 mL of pH 6.8 phosphate buffer.
- Example 1-2 the dissolution rate was 92%, and in Comparative Example 1-2, 82%. It was shown that the orally disintegrating tablet packaged in the package P of Example 1 retains high dissolution properties. It was.
- Orally disintegrating tablets are tablets that disintegrate in the oral cavity with saliva or a small amount of water, and are required to dissolve (disintegrate) rapidly in the oral cavity.
- the orally disintegrating tablet is not preferably stored, the dissolution is delayed and it is difficult to dissolve (disintegrate) in a short time.
- the dissolution delay of an orally disintegrating tablet was suppressed by the package P of this invention, and it has high dissolution property in a short time. This result is presumed that the adsorption layer 1 provided in the package P of the present invention effectively adsorbs water and the like, and thus contributes to the stabilization of the orally disintegrating tablet of the adsorption layer 1.
- the packaging body film used for the packaging body P of this invention is not limited to the structure of said packaging body film F1.
- the packaging film F1 only the base material layer 2 is provided as the base material layer, but a plurality of base material layers (main base materials) are used as the base material layer as in the packaging film F2 shown in FIG.
- the structure provided with the layer 2a and the sub-base material layer 2b) may be sufficient.
- FIG. 8 is a schematic cross-sectional view of a packaging body film F2 according to another embodiment of the present invention. Since the structure and action of the adsorption layer 1, the aluminum foil 3, and the barrier layer 4 are the same as those of the packaging film F1, description thereof is omitted.
- the main base material layer 2a and the sub base material layer 2b are provided in order to impart appropriate rigidity and moldability to the packaging body film F2, similarly to the base material layer 2. And the main base material layer 2a and the sub base material layer 2b are comprised with the material similar to the said base material layer 2.
- FIG. 1 is a schematic cross-sectional view of a packaging body film F2 according to another embodiment of the present invention. Since the structure and action of the adsorption layer 1, the aluminum foil 3, and the barrier layer 4 are the same as those of the packaging film F1, description thereof is omitted.
- the main base material layer 2a and the sub base material layer 2b are provided in order to impart appropriate rigidity and moldability to the packaging body film F2, similarly to the base material
- the compounding amount of the drug is not particularly limited as long as it is a pharmaceutically preventive or therapeutically effective amount, but is usually 10 ng or more and 5000 mg or less per day, and as another embodiment, 500 ⁇ g or more and 1000 mg or less, Administered to patients at an adult dosage level of 1 mg to about 100 mg.
- the compounding ratio is usually appropriately selected according to the type, use (indication), and age (or body weight) of the drug, but is particularly limited if it is a therapeutically effective amount or a prophylactically effective amount. Not.
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Food Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Composite Materials (AREA)
- Packages (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Laminated Bodies (AREA)
- Wrappers (AREA)
Abstract
Description
本発明は、包装体に係り、特に吸湿性及びガス吸着性を備えると共に成形性の高い包装体に関する。 The present invention relates to a package, and more particularly to a package having high hygroscopicity and gas adsorbability and high moldability.
従来、医薬品の包装においては、プレススルーパック(PTP)包装体が広く用いられている。PTP包装体は、容器に被包装物を収容した後、破れやすい蓋材によってシールする形態の包装体であり、容器側から蓋材側に向かって押圧することにより蓋材が破れ、被包装物が取り出される。このようなPTP包装体は、気密性、取り扱い性、携帯性、生産性に優れ、且つ省資源化できることから、医薬品の包装体として、今後の需要はさらに高くなると予想される。 Conventionally, a press-through pack (PTP) package has been widely used for packaging pharmaceutical products. The PTP package is a package in a form that is sealed with a lid material that is easy to tear after the packaged material is accommodated in the container, and the lid material is torn by pressing from the container side toward the lid material side. Is taken out. Since such a PTP package is excellent in airtightness, handleability, portability, and productivity and can save resources, it is expected that the future demand will be further increased as a package for pharmaceutical products.
PTP包装体の容器側の材料としては、ポリプロピレンシート又はポリ塩化ビニルシートの単層体や、アルミニウム箔にフィルム等を積層させた複数の材料からなる積層体が用いられるのが一般的である。また、蓋材側の材料としては、樹脂をコーティングしたアルミニウム箔等が用いられることが多い。 As the material on the container side of the PTP package, it is common to use a single layer of a polypropylene sheet or a polyvinyl chloride sheet, or a laminate composed of a plurality of materials in which a film or the like is laminated on an aluminum foil. Moreover, as the material on the lid member side, an aluminum foil coated with a resin is often used.
このように、多様な材料が用いられる包装体の中でも、水分で分解する薬物を含んでいたり、被包装体が吸湿性の高いものであったりする場合、包装体の材料として、水の透過性が低いポリ塩化ビニリデン、PCTFE(三フッ化クロロエチレン樹脂)等が用いられ、密封することにより、防湿性を高めていた。 In this way, among the packaging bodies in which various materials are used, when a drug that decomposes with moisture is contained or the packaged body is highly hygroscopic, water permeability can be used as the packaging body material. Polyvinylidene chloride, PCTFE (chlorofluoride trifluoride resin), etc., which have a low viscosity, were used, and the moisture resistance was improved by sealing.
しかし、加水分解性、又は吸湿性の高い被包装体に対して密封する包装を施しても、ポケット(被包装体を収容する部分)の表面や、蓋材の端部からの透湿があり、防湿性が不十分となることから、被包装体の保護効果が比較的小さいという問題点があった。 However, even if packaging that seals against a hydrolyzable or highly hygroscopic package body, there is moisture permeability from the surface of the pocket (portion that contains the package body) or from the end of the lid. Since the moisture-proof property is insufficient, there is a problem that the protective effect of the packaged body is relatively small.
これに対し、特許文献1では、防湿性の高いアルミニウム箔を用いた容器及び蓋材を貼り合わせた構成のPTP包装体が提案されている。特許文献1のPTP包装体において、容器を構成するアルミニウム箔には、その一面に延伸されたポリアミド系樹脂層が設けられており、他面に熱接着層が設けられている。そして、少なくともアルミニウム箔を含む蓋材、又は容器を構成するアルミニウム箔と同様の構成のアルミニウム箔と、容器とがヒートシールされることにより、防湿性を備えたPTP包装体とすることができる。
On the other hand,
また、特許文献2では、PTP包装体の容器に吸湿層を設け、PTP包装体に乾燥機能を付与する技術が提案されている。乾燥機能が付与されたPTP包装体は、被包装体に対して乾燥機能を作用させることができるため、被包装体が加水分解性、又は吸湿性の高いものであっても良好な保存状態とすることができる。
In
特許文献1で開示された技術では、容器を構成する材料として防湿性の高いアルミニウムが用いられており、蓋材もまたアルミニウムによって構成されている。そして、容器と蓋材とをヒートシールすることにより、防湿性を備えたPTP包装体を提供することが可能であるが、被包装体を封入した場合、その被包装体が封入された部分(収容部)の内部に残留した水分が除去できず、固形製剤の品質が損なわれるという問題点があった。したがって、防湿のみならず吸湿する能力のあるPTP包装体が望まれていた。また、被包装体によっては、分解時に発生するガスにより更に分解が促進される性質があるため、水分のみならずガスを吸着させる能力のあるPTP包装体が望まれていた。
In the technique disclosed in
これに対し、特許文献2で開示された技術においては、吸湿層が備えられることにより、被包装体及び被包装体が封入された内部(収容部)に対して乾燥機能が付与されたPTP包装体とすることができる。
On the other hand, in the technique disclosed in
特許文献2で開示されたPTP包装体(ブリスター包装体)は、防湿性のバリアー層に対して吸湿層を貼り合わせることによってフィルムを作成し、このフィルムを用いることによってPTP包装体を形成する。このとき、バリアー層と吸湿層とを備えたフィルムは、加熱軟化させた状態で、被包装物を収容する収容部が形成される。
The PTP package (blister package) disclosed in
このように、加熱によって成形を行う技術においては、各層の熱収縮率が異なる場合、成形性が低下する虞があるという不都合がある。したがって、吸湿性を備えると共に、成形性の良いPTP包装体を提供することが可能な技術が望まれていた。 As described above, in the technique of performing molding by heating, there is a disadvantage that the moldability may be lowered when the thermal shrinkage rate of each layer is different. Therefore, a technique capable of providing a PTP package having hygroscopicity and good moldability has been desired.
また、PTP包装体においては、被包装体を収容する収容部(ポケット)の剛性が不十分であると、内部に被包装体を収容しにくくなるだけでなく、収容部に外力が加わった場合、容易に収容部が潰れてしまうため、封入された被包装体を保護する効果が小さい。さらに、包装体を構成するフィルムに適度な剛性がない場合、包装体の収容部を形成する際、成形性が低下する。したがって、防湿性を確保すると共に、適度な剛性を備え、被包装体を物理的に保護することが可能な技術が望まれていた。 Moreover, in the PTP package, when the rigidity of the accommodating part (pocket) for accommodating the packaged body is insufficient, not only is it difficult to accommodate the packaged object inside, but an external force is applied to the accommodating part. Since the housing portion is easily crushed, the effect of protecting the sealed packaged body is small. Furthermore, when the film which comprises a package does not have moderate rigidity, when forming the accommodating part of a package, a moldability falls. Therefore, there has been a demand for a technique capable of ensuring moisture resistance, having appropriate rigidity, and physically protecting the packaged body.
本発明の目的は、吸湿性及びガス吸着性を備えると共に、成形性が良好な包装体を提供することにある。また、本発明の他の目的は、吸湿性及びガス吸着性を備えると共に、適度な剛性を備えた包装体を提供することにある。 An object of the present invention is to provide a package having a hygroscopic property and a gas adsorbing property and having good moldability. In addition, another object of the present invention is to provide a package body having a hygroscopic property and a gas adsorbing property and having an appropriate rigidity.
前記課題は、本発明に係る包装体によれば、コハク酸ソリフェナシンまたは1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸を含有する固形製剤を収容する包装体であって、該包装体は、前記固形製剤を収容する凹状の収容部が形成された容器用シートと、前記固形製剤を封止する気密性を備えた蓋材シートと、を備え、前記容器用シートは、吸着層と、樹脂によって構成される少なくとも一層以上の基材層と、アルミニウム箔と、バリア層とが積層された包装体フィルムからなり、前記吸着層は、前記基材層と積層されると共に前記固形製剤が収容される側に配設され、少なくともゼオライトを含有してなることにより解決される。 The object is to provide a package containing a solid preparation containing solifenacin succinate or 1-{[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid according to the package according to the present invention. The package body is provided with a container sheet in which a concave container for containing the solid preparation is formed, and a lid sheet with airtightness for sealing the solid preparation, The container sheet is composed of a packaging film in which an adsorption layer, at least one base layer composed of a resin, an aluminum foil, and a barrier layer are laminated, and the adsorption layer includes the base layer and the base layer. This is solved by being laminated and disposed on the side where the solid preparation is accommodated, and containing at least zeolite.
このように、本発明の包装体を構成する容器用シートは、固形製剤が収容される側においてゼオライトを含有した吸着層を備えているため、収容部内の水や、その他の分子(気体分子)を吸着することができる。そしてさらに、容器用シートには防湿性の高いアルミニウム箔が備えられているため、吸着層と組み合わされることにより、包装体の防湿性が飛躍的に向上する。
また、本発明の包装体の容器用シートを構成する包装体フィルムは、吸着層に積層される基材層を少なくとも一層以上備えているため、適度な剛性が付与される。したがって、収容部を設けた容器用シートの製造時、成型性が良好であり、且つ固形製剤が収容される収容部もまた、適度な剛性を備えている。したがって、包装体内に収容される固形製剤を十分に保護すると共に、PTP包装体としたとき、適度な外力によって固形製剤を取り出すことができる。
特に、1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸は、加水分解性の物質であり、加水分解反応により、臭気の原因となるアセトアルデヒドを生成する。また、上記化合物を含む固形製剤は、吸湿により着色しやすい。したがって、その包装体には高い吸湿性及びガス吸着性が求められる。
本発明の包装体は、吸着層によって水やアセトアルデヒド等を吸着することにより、不快な臭いの発生や、固形製剤の着色を防止することが可能となる。その結果、上記化合物を含む固形製剤の保存状態を良好に保持することができる。
Thus, since the container sheet constituting the package of the present invention includes the adsorption layer containing zeolite on the side where the solid preparation is accommodated, water in the accommodating portion and other molecules (gas molecules) Can be adsorbed. Furthermore, since the container sheet is provided with a highly moisture-proof aluminum foil, the moisture resistance of the package is dramatically improved by being combined with the adsorption layer.
Moreover, since the packaging body film which comprises the container sheet | seat of the packaging body of this invention is equipped with the base material layer laminated | stacked on an adsorption layer, moderate rigidity is provided. Therefore, at the time of manufacture of the container sheet provided with the accommodating portion, the moldability is good, and the accommodating portion in which the solid preparation is accommodated also has appropriate rigidity. Therefore, the solid preparation contained in the package is sufficiently protected, and when the PTP package is used, the solid preparation can be taken out with an appropriate external force.
In particular, 1-{[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid is a hydrolyzable substance, and generates acetaldehyde that causes odor by the hydrolysis reaction. Moreover, the solid preparation containing the compound is easily colored by moisture absorption. Accordingly, the package is required to have high moisture absorption and gas adsorption.
The package of the present invention can prevent generation of unpleasant odors and coloring of solid preparations by adsorbing water, acetaldehyde and the like by the adsorption layer. As a result, the preservation state of the solid preparation containing the compound can be favorably maintained.
また、前記基材層は、ポリアミド系樹脂又はポリ塩化ビニル樹脂からなると好適である。
基材層として、上記材料を用いることにより、包装体フィルムに適度な剛性を付与することができる。その結果、包装体を構成する容器用シートを成形する際、プレス加工により容易に成形することが可能となる。
The base material layer is preferably made of a polyamide resin or a polyvinyl chloride resin.
By using the above material as the base material layer, an appropriate rigidity can be imparted to the packaging film. As a result, when the container sheet constituting the package is formed, it can be easily formed by press working.
このとき、前記収容部の直径に対する前記収容部の高さの比は、0.335を上限として成形されてなると好適である。
一般には、フィルムを伸ばすほどピンホールの発生率が高くなることが予想される。したがって、収容される錠剤またはカプセル剤等の医薬品製剤の形状または大きさに合わせてプレス加工により成形される収容部を設計する際に、必要な高さを確保するために収容部の間口を適宜大きくし、収容部の直径に対する収容部の高さの比(収容部の高さ/収容部の直径)をそれぞれのフィルム独自の目標値以下に規定することがある。また、異形錠の場合は、ポケット間口の短径に対する収容部の高さを元に設計を行うことができる。
このように、収容部の高さと収容部の直径の比を上記の数値以下とすることにより、包装体の容器用シートの成形時、ピンホールの発生を防止することができる。一般に、包装体フィルムをプレス加工することによって容器用シートを形成する際、収容部の直径に対する収容部の高さの比が大きいほど、収容部天面と収容部側面との境界部分(肩R部)付近において、包装体フィルム中のアルミニウム箔にピンホールが生じる。特に、包装体フィルムを加熱しないプレス加工により容器用シートを形成する場合は、収容部の直径に対する収容部の高さの比が上記数値よりも大きい場合、収容部のピンホール発生確率が高くなるが、上記数値以下とすることにより、ピンホールの発生確率をほぼ0とすることができる。したがって、包装体フィルムをプレス加工する際、収容部にピンホールが発生しにくいため、防湿性の優れた包装体とすることができる。
At this time, it is preferable that the ratio of the height of the housing portion to the diameter of the housing portion is formed with 0.335 as an upper limit.
In general, it is expected that the pinhole occurrence rate increases as the film is stretched. Therefore, when designing a storage part to be molded by press processing according to the shape or size of a pharmaceutical preparation such as a tablet or capsule to be stored, an appropriate frontage of the storage part is used to ensure the required height. In some cases, the ratio of the height of the accommodating portion to the diameter of the accommodating portion (the height of the accommodating portion / the diameter of the accommodating portion) is regulated to be equal to or less than a target value unique to each film. Moreover, in the case of a deformed tablet, it can design based on the height of the accommodating part with respect to the short diameter of a pocket frontage.
Thus, by making the ratio of the height of the storage portion and the diameter of the storage portion equal to or less than the above numerical value, the occurrence of pinholes can be prevented when the container sheet of the package is formed. Generally, when forming a container sheet by pressing a packaging body film, the larger the ratio of the height of the housing portion to the diameter of the housing portion, the larger the boundary portion between the top surface of the housing portion and the side surface of the housing portion (shoulder R Part) vicinity, a pinhole arises in the aluminum foil in a packaging body film. In particular, when the container sheet is formed by press working that does not heat the packaging film, if the ratio of the height of the container to the diameter of the container is larger than the above value, the probability of occurrence of pinholes in the container increases. However, if the value is less than or equal to the above value, the probability of occurrence of pinholes can be made substantially zero. Therefore, when the packaging body film is pressed, a pinhole is unlikely to be generated in the housing portion, so that the packaging body having excellent moisture resistance can be obtained.
さらに、前記蓋材シートは、アルミニウム箔を備えてなると好ましい。
蓋材シートがアルミニウム箔を備えた構成とすると、容器用シートに形成された固形製剤の収容部と蓋材シートとの防湿性を向上させることができる。その結果、容器用シートに形成された収容部の内部に備えられた吸着層によって、収容部内の水、気体分子が吸着されるため、防湿性が向上する。
また、蓋材シートをアルミニウム箔によって構成すると、PTP包装体としたときに、容器用シート側から加えられた外力によって破れやすくなり、その結果、収容部内の固形製剤を取り出し易いため好適である。
Furthermore, it is preferable that the lid sheet is provided with an aluminum foil.
When the lid sheet is provided with an aluminum foil, the moisture resistance between the solid formulation container formed on the container sheet and the lid sheet can be improved. As a result, water and gas molecules in the storage portion are adsorbed by the adsorption layer provided in the storage portion formed in the container sheet, so that moisture resistance is improved.
In addition, when the lid sheet is made of aluminum foil, it is preferable that the PTP package is easily broken by an external force applied from the container sheet side, and as a result, the solid preparation in the container can be easily taken out.
また、前記ゼオライトの有効細孔径は、3Å以上であると好適である。
ゼオライトは、吸着速度が速いため水分を素速く吸着することができる。ゼオライトの一例であるモレキュラーシーブは、分子の大きさの違いによって物質を分離するのに用いられる多孔質の粒状物質であり、均一な細孔をもつ構造であって、細孔の空洞に入る小さな分子を吸着して一種のふるいの作用を有する。本発明において、モレキュラーシーブを用いる場合、その吸着口径は、0.3nm~1nmが好ましい。通常、細孔径が0.3nm、0.4nm、0.5nm、1nmのモレキュラーシーブを、それぞれモレキュラーシーブ3A、モレキュラーシーブ4A、モレキュラーシーブ5A、モレキュラーシーブ13Xと称する。本実施形態では、モレキュラーシーブ3A又はモレキュラーシーブ4Aが好適な乾燥剤として用いられる。また、モレキュラーシーブの平均粒子径は、例えば10μm前後のものが用いられる。
そして、一般に、ゼオライトによって吸着される物質は、ゼオライトの有効細孔径に依存する。
ゼオライトの有効細孔径が、4Å未満であると、水は吸着できるものの、二酸化炭素及びアセトアルデヒド等の比較的大きな分子を十分に吸着できない。これに対し、ゼオライトの有効細孔径を4Å以上とすると、水、二酸化炭素、アセトアルデヒド、硫化水素、エタン、エタノール等の比較的大きな分子も吸着可能となる。
したがって、水のみが固体製剤の保存状態に影響を及ぼす場合には、ゼオライトの有効細孔径が3Å以上であると固形製剤を良好な状態で保存することができる。さらに、ゼオライトの有効細孔径が4Å以上であると硫化水素等の臭気を発する物質や、エタノール等の固体製剤の保存状態に影響を及ぼす可能性がある物質も吸着層によって吸着されるため、良好な保存状態で固体製剤を保存することができる。
The effective pore diameter of the zeolite is preferably 3 mm or more.
Since zeolite has a high adsorption rate, it can adsorb moisture quickly. Molecular sieve, which is an example of zeolite, is a porous granular material used to separate materials according to the difference in molecular size, and has a structure with uniform pores. It acts as a kind of sieve by adsorbing molecules. In the present invention, when a molecular sieve is used, the adsorption port diameter is preferably 0.3 nm to 1 nm. In general, molecular sieves having pore sizes of 0.3 nm, 0.4 nm, 0.5 nm, and 1 nm are referred to as molecular sieve 3A, molecular sieve 4A, molecular sieve 5A, and molecular sieve 13X, respectively. In the present embodiment, molecular sieve 3A or molecular sieve 4A is used as a suitable desiccant. The average particle diameter of the molecular sieve is, for example, about 10 μm.
In general, the substance adsorbed by the zeolite depends on the effective pore size of the zeolite.
If the effective pore size of the zeolite is less than 4 mm, water can be adsorbed but relatively large molecules such as carbon dioxide and acetaldehyde cannot be adsorbed sufficiently. On the other hand, when the effective pore diameter of the zeolite is 4 mm or more, relatively large molecules such as water, carbon dioxide, acetaldehyde, hydrogen sulfide, ethane, and ethanol can be adsorbed.
Therefore, when only water affects the storage state of the solid preparation, the solid preparation can be stored in a good state when the effective pore diameter of the zeolite is 3 mm or more. Furthermore, if the effective pore size of the zeolite is 4 mm or more, substances that emit odors such as hydrogen sulfide and substances that may affect the storage state of solid preparations such as ethanol are also adsorbed by the adsorption layer, which is good. The solid preparation can be stored in a safe storage state.
本発明の包装体によれば、容器用シートを構成する包装体フィルムにおいて吸着層が設けられ、さらにその上層には基材層、アルミニウム箔が備えられている。したがって、包装体は、アルミニウム箔により防湿性が高いだけでなく、吸着層で固形製剤の収容部内の水及び気体分子を吸着することによって吸湿性が向上し、基材層によって適度な剛性が付与される。
本発明の包装体は、適度な剛性が付与された結果、加熱をしないプレス加工によって容易に加工することが可能となり、成形性が飛躍的に改善される。そして、成形性の向上に伴い、その歩留まりが向上する。さらに、適度な剛性が付与された結果、本発明の包装体は、固形製剤の保存状態を良好にすることが可能となる。
また、固形製剤を収容する収容部の直径に対する収容部の高さの比を所定の高さ以下とすることにより、特に収容部近傍においてピンホールの発生を防止することができる。
さらに、蓋材シートにもアルミニウム箔を備えることにより、防湿性がさらに向上する。
さらにまた、吸着層に含有されるゼオライトの有効細孔径を所定の値以上とすることにより、水だけでなく、その他の気体分子等も吸着可能となるので、臭気の発生や、固形製剤の着色も防止することができ、良好な保存状態で固形製剤を保存可能となる。
According to the packaging body of the present invention, the adsorption layer is provided in the packaging body film constituting the container sheet, and the base layer and the aluminum foil are further provided thereon. Therefore, the package is not only highly moisture-proof due to the aluminum foil, but also the moisture absorption is improved by adsorbing water and gas molecules in the container of the solid preparation by the adsorption layer, and appropriate rigidity is imparted by the base material layer. Is done.
As a result of imparting appropriate rigidity, the package of the present invention can be easily processed by pressing without heating, and the moldability is dramatically improved. And the yield improves with the improvement of a moldability. Furthermore, as a result of imparting appropriate rigidity, the package of the present invention can improve the storage state of the solid preparation.
In addition, by setting the ratio of the height of the storage portion to the diameter of the storage portion that stores the solid preparation to be a predetermined height or less, it is possible to prevent the occurrence of pinholes particularly in the vicinity of the storage portion.
Furthermore, moisture resistance is further improved by providing the lid sheet with an aluminum foil.
Furthermore, by setting the effective pore diameter of the zeolite contained in the adsorption layer to a predetermined value or more, not only water but also other gas molecules can be adsorbed. And the solid preparation can be stored in a good storage state.
P 包装体
F1,F2 包装体フィルム
1 吸着層
2 基材層
2a 主基材層
2b 副基材層
3 アルミニウム箔
4 バリア層
5 収容部
6 容器用シート
7 蓋材シート
8 固形製剤
P packaging body F1, F2
以下、本発明の一実施形態について、図を参照して説明する。なお、以下に説明する部材、配置等は、本発明を限定するものではなく、本発明の趣旨に沿って各種改変することができることはもちろんである。 Hereinafter, an embodiment of the present invention will be described with reference to the drawings. The members, arrangements, and the like described below do not limit the present invention, and various modifications can be made in accordance with the spirit of the present invention.
図1乃至図6は本発明の一実施形態に係るもので、図1は包装体フィルムの概略断面図、図2は包装体の概略断面図、図3乃至図6は本発明の実施例1、比較例1及び2における色差測定結果のグラフ図、図7は本発明の実施例1、比較例1及び2における溶出度のグラフ図であり、図8は本発明の他の実施形態に係る包装体フィルムの概略断面図である。
1 to 6 relate to an embodiment of the present invention, FIG. 1 is a schematic cross-sectional view of a packaging body film, FIG. 2 is a schematic cross-sectional view of the packaging body, and FIGS. 3 to 6 are
(包装体フィルムF1の構成)
本発明の一実施形態に係る包装体フィルムF1は、図1で示すように吸着層1と、少なくとも一層以上の基材層2と、アルミニウム箔3とバリア層4とがこの順に積層されて構成されている。なお、図1の下方側に被包装体が配設される。
(Configuration of packaging film F1)
As shown in FIG. 1, the packaging body film F1 according to one embodiment of the present invention is constituted by laminating an
吸着層1は、樹脂とゼオライトをインフレーション法、Tダイ法、共押出等によってフィルム状又はシート状に形成したものが好適に用いられる。
また、吸着層1の厚さは、十分な量の水分、ガスを吸着するため、その厚さは30~100μmとすると好ましい。
The
The thickness of the
吸着層1を構成する樹脂の材料としては、LDPE(低密度ポリエチレン)、LLDPE(直鎖状低密度ポリエチレン)、PP(ポリプロピレン)、塩素化ポリプロピレン、飽和ポリエステル、EAA(エチレン-アクリル酸共重合体)、EMAA(エチレン-メタクリル酸共重合体)、EEA(エチレン-エチルアクリレート共重合体)、EMA(エチレン-メチルアクリレート共重合体)、アイオノマー、カルボン酸変性ポリエチレン、カルボン酸変性ポリプロピレン、カルボン酸変性EVA、PVC(ポリ塩化ビニル)、ポリスチレン等から選ばれる少なくとも1種、又はこれらを組み合わせて用いることができる。
なお、吸着層1の両面にスキン層を配置しても良い。スキン層の材料としては、(1)ゼオライトを含有している層が表面に露出して製剤と直接接触するのを防ぐ、または(2)ラミネート性を向上させるものであれば特に制限されない。スキン層の材料としては、例えば、LDPE(低密度ポリエチレン)、LLDPE(直鎖状低密度ポリエチレン)、PP(ポリプロピレン)、塩素化ポリプロピレン、飽和ポリエステル、EAA(エチレン-アクリル酸共重合体)、EMAA(エチレン-メタクリル酸共重合体)、EEA(エチレン-エチルアクリレート共重合体)、EMA(エチレン-メチルアクリレート共重合体)、アイオノマー、カルボン酸変性ポリエチレン、カルボン酸変性ポリプロピレン、カルボン酸変性EVA、PVC(ポリ塩化ビニル)、ポリスチレン等から選ばれる少なくとも1種、又はこれらを組み合わせて用いることができる。
Examples of the resin material constituting the
In addition, you may arrange | position a skin layer on both surfaces of the
また、吸着層1を構成するゼオライトは、モレキュラーシーブを含むものであり、モレキュラーシーブは、その有効細孔径が3~10Å程度であると好ましい。モレキュラーシーブは、吸着する対象物の大きさに合わせて、その有効細孔径を選択する。特に、有効細孔径を4Å以上とすると、水だけでなく、二酸化炭素、アセトアルデヒド、硫化水素、エタン、エタノール等の気体分子を吸着することができる。また、固体製剤8が分解した際、アセトアルデヒド、硫化水素等の臭気の原因となる物質を発生するような場合もまた、吸着層1に吸着されるため好ましい。
Further, the zeolite constituting the
また、人工ゼオライトは、工業的な方法により、種々の物質から天然ゼオライトに性質が類似した物質を形成したものである。そのため、吸着性や、イオン交換性などが向上されている。したがって、吸着する物質に応じて、吸着層1を構成するゼオライトの材料を適宜選択すると良い。
In addition, artificial zeolite is obtained by forming a substance similar in nature to natural zeolite from various substances by an industrial method. Therefore, the adsorptivity and ion exchange properties are improved. Therefore, the zeolite material constituting the
基材層2は、吸着層1に貼り合わされる樹脂からなる層であり、主に包装体フィルムF1に適度な剛性及び成形性を付与する。基材層2の材料としては、ポリ塩化ビニル、ポリプロピレン、ポリ塩化ビニリデン、ナイロン(登録商標)等のポリアミド、等から選ばれる少なくとも1種、又はこれらを組み合わせて用いることができる。これらの中でも、ナイロン(登録商標)等のポリアミド、PVC(ポリ塩化ビニル)が好ましく、特に、適度な伸び性を備えたPVC(ポリ塩化ビニル)が好ましい。ポリ塩化ビニルを選択すると、包装体フィルムF1の成形性及び剛性を良好に保つことができ、また、プレス加工により、後述する包装体Pを成形する際、ピンホールの発生を防止することができる。
また、基材層2の厚さは、包装体フィルムF1の剛性を確保し、良好な成形性を保持するため、15~25μmとすると好ましい。
The
The thickness of the
アルミニウム箔3は、純アルミニウム箔又はアルミニウム合金箔の何れであっても良い。さらに、純アルミニウム箔にPP(ポリプロピレン)系等、樹脂をコーティングしたものであっても良い。
また、アルミニウム箔3の厚さは、良好な成形性を保持すると共に、容器の耐湿性、遮光性を保ち、さらに適度な剛性、及び成形性を付与するため、30~60μmとすると好ましい。
The
In addition, the thickness of the
バリア層4は、密封可能なフィルム状材料から形成される。バリア層4を構成する材料としては、例えばHDPE(高密度ポリエチレン)、MDPE(中密度ポリエチレン)、LDPE(低密度ポリエチレン)、ポリ塩化ビニリデン、ポリクロロトリフルオロエチレン、PP(ポリプロピレン)、ポリエチレンテレフタレート、及びナイロン(登録商標)等のポリアミド、等から選ばれる少なくとも1種、又はこれらを組み合わせて用いることができる。中でも、ナイロン(登録商標)等のポリアミドを選択すると、成形性が向上するため好ましい。そして、十分な密閉性を保持すると共に適度な成形性を保持するため、バリア層4は、5~30μmとすると好ましい。
The
また、上記吸着層1、基材層2、アルミニウム箔3、バリア層4との間には、それぞれ接着層(不図示)が設けられていても良い。接着層(不図示)としては、例えば、ウレタン系接着剤、HDPE(高密度ポリエチレン)、MDPE(中密度ポリエチレン)、LDPE(低密度ポリエチレン)、ポリプロピレン、塩素化ポリプロピレン、飽和ポリエステル、EAA(エチレン-アクリル酸共重合体)、EMAA(エチレン-メタクリル酸共重合体)、EEA(エチレン-エチルアクリレート共重合体)、EMAC(エチレン-メチルアクリレート共重合体)、アイオノマー、カルボン酸変性ポリエチレン、カルボン酸変性ポリプロピレン、カルボン酸変性EVA、PVC(ポリ塩化ビニル)、ポリスチレン等から選ばれる少なくとも1種、又はこれらを組み合わせて用いることができる。また、接着層(不図示)の厚さは10μm程度とすると好ましい。
Further, an adhesive layer (not shown) may be provided between the
また、上記吸着層1、基材層2、アルミニウム箔3、バリア層4の各層は、公知の方法で張り合わせることができ、押出ラミネーション、ドライラミネーション、ウェットラミネーション、サーマルラミネーション、サンドラミネーション等の方法により張り合わせることができる。
Moreover, each layer of the said
上記のように、吸着層1、基材層2、アルミニウム箔3、バリア層4からなる包装体フィルムF1は、後述する包装体Pを成形するために適当な剛性を備えていれば良い。したがって、各層の膜厚の総計、すなわち包装体フィルムF1の膜厚は、120~200μm程度とすると好ましい。
As described above, the packaging body film F1 composed of the
(包装体Pの構成)
本発明の一実施形態に係る包装体Pは、図2に示すように、上記包装体フィルムF1によって形成される容器用シート6と、気密性を備えた蓋材シート7と、によって形成されており、収容部5の内部に、固形製剤8を包装するものである。なお、図2は、説明のため、容器用シート6の厚みを誇張して示している。
(Structure of package P)
As shown in FIG. 2, the packaging body P according to an embodiment of the present invention is formed by a
容器用シート6は、吸着層1と、少なくとも一層以上の基材層2と、アルミニウム箔3と、バリア層4とが積層された包装体フィルムF1によって形成されている。そして、容器用シート6は、包装体フィルムF1を用いて固形製剤8を収容する凹状の収容部5が1個または複数形成されている。
The
容器用シート6は、図2のように、固形製剤8が収容される側の面に吸着層1が配設される構成である。この構成により、収容部5内及び固形製剤8の内部に含有された水、又は固形製剤8中に含まれる薬剤が水と反応することにより発生する気体が、吸着層1により吸収される。したがって、収容部5内に収容される固形製剤8は、成分が劣化することなく、好適な保存状態で保存することができる。
The
上記構成の容器用シート6は、包装体フィルムF1に対してプレス成形等の手法により収容部5が1個または複数形成される。なお、収容部5の形状は、内部に収容される固形製剤8の形状に依存して適宜設計される。プレス成形の方法は特に限定されないが、張り出し成形、深絞り成形等、公知の手法が用いられる。
The
蓋材シート7は、容器用シート6の吸着層1が設けられた面に密着し、固形製剤8が収容された収容部5の内部を密閉する。
なお、容器用シート6と、蓋材シート7との密着性が低い場合は、吸着層1の蓋材シート7と対向する側の表面に、ヒートシール性樹脂層(不図示)を設けても良い。ヒートシール性樹脂層の材料としては、上記の接着層(不図示)と同等の材料を用いることができる。
The
If the adhesion between the
蓋材シート7は、水蒸気等の気体の流出入を防ぐことのできる性質を有する密封可能なフィルム状材料から形成される。蓋材シート7を構成する材料としては、例えばアルミニウム、高密度ポリエチレン、中密度ポリエチレン、低密度ポリエチレン、ポリ塩化ビニリデン、ポリクロロトリフルオロエチレン、及びポリプロピレン、ナイロン(登録商標)等のポリアミド、等から選ばれる少なくとも1種、又はこれらを組み合わせて用いることができる。中でも、アルミニウムを用いると、容器の耐湿性、遮光性が向上するため好ましい。アルミニウムを用いた場合、容器用シート6と対向する側の表面に接着剤が塗布されていると好ましい。この時用いられる接着剤としては、エチレン-酢酸ビニル共重合体、ポリ塩化ビニリデン、塩化ビニル-酢酸ビニル共重合体、塩素化ポリプロピレン等を用いることができる。なお、アルミニウムは、純アルミニウム又はアルミニウム合金の何れであっても良い。
The
(試験例1:容器用シート6の剛性試験)
基材層2をPA、又はPVCとした場合における容器用シート6の収容部5の強度(外力に対する潰れにくさ)を評価したところ、何れも包装体として十分な強度を有していたが、PAを用いた場合(実施例1)と比較して、PVCを用いた場合(実施例2)の方が、収容部5の強度が高く、潰れにくいことが示された。結果を、以下の表1に示す。
(Test Example 1: Stiffness test of container sheet 6)
When evaluating the strength of the
上記結果より、基材層2としてPVCを用いた場合、PAを用いた場合と比較して収容部5の強度が約2倍向上することが示された。実施例1及び実施例2の容器用シート6を構成する包装体フィルムF1の構成を以下に示す。
From the above results, it was shown that when PVC is used as the
((実施例1))
[包装体フィルムF1の構成]
吸着層1:ゼオライト(ユニオン昭和株式会社製、商品名:モレキュラーシーブ4A、有効細孔径:4Å)含有LDPE(東ソー株式会社製、商品名:ペトロセン202、厚さ:50μm)層の両面にLLDPE(株式会社プライムポリマー製、商品名:エボリュー(登録商標)SP2520)のスキン層が積層された2種3層
基材層2:PA(ポリアミド系樹脂)(株式会社興人製、商品名:ボニールW、厚さ:15μm)
アルミニウム箔3:合金アルミニウム箔(東洋アルミニウム株式会社製、商品名:スーパーホイル、厚さ:40μm)
バリア層4:PA(ポリアミド系樹脂)(株式会社興人製、商品名:ボニールW、厚さ:15μm)
((Example 1))
[Configuration of Packaging Film F1]
Adsorption layer 1: LLDPE (both LLDPE (made by Tosoh Corporation, trade name: Petrocene 202, thickness: 50 μm)) containing LDPE (made by Union Showa Co., Ltd., trade name: molecular sieve 4A, effective pore size: 4 mm) Made of Prime Polymer Co., Ltd., trade name: Evolue (registered trademark) SP2520)
Aluminum foil 3: Alloy aluminum foil (manufactured by Toyo Aluminum Co., Ltd., trade name: super foil, thickness: 40 μm)
Barrier layer 4: PA (polyamide resin) (manufactured by Kojin Co., Ltd., trade name: Bonile W, thickness: 15 μm)
((実施例2))
[包装体フィルムF1の構成]
吸着層1:ゼオライト(ユニオン昭和株式会社製、商品名:モレキュラーシーブ4A、有効細孔径:4Å)含有LDPE(東ソー株式会社製、商品名:ペトロセン202、厚さ:50μm)層の両面にLLDPE(株式会社プライムポリマー製、商品名:エボリュー(登録商標)SP2520)のスキン層が積層された2種3層
基材層2:PVC(ポリ塩化ビニル)(厚さ:60μm)
アルミニウム箔3:合金アルミニウム箔(住軽アルミ箔株式会社製、商品名:BESPAII、厚さ:40μm)
バリア層4:PA(ポリアミド系樹脂)(東洋紡績株式会社製、商品名:ハーデンN2102、厚さ:15μm)
((Example 2))
[Configuration of Packaging Film F1]
Adsorption layer 1: LLDPE (on both sides of the LDPE (product name: Petrocene 202, thickness: 50 μm) layer containing zeolite (manufactured by Union Showa Co., Ltd., trade name: Molecular sieve 4A, effective pore size: 4 mm)) Made of Prime Polymer Co., Ltd., trade name: Evolue (registered trademark) SP2520) skin layer laminated, 2 types and 3 layers Base material layer 2: PVC (polyvinyl chloride) (thickness: 60 μm)
Aluminum foil 3: Alloy aluminum foil (manufactured by Sumi Light Aluminum Foil Co., Ltd., trade name: BESP AII, thickness: 40 μm)
Barrier layer 4: PA (polyamide resin) (manufactured by Toyobo Co., Ltd., trade name: Harden N2102, thickness: 15 μm)
(試験例2:容器用シート6の成形性試験)
一般に、収容部5の直径(ポケット径)を一定にした条件において、収容部5の高さは、包装体フィルムF1において収容部5が形成される部分に発生するピンホールに関係しており、ポケット径に対する収容部5の高さの比(収容部5の高さ/ポケット径の比)が大きくなるほど、ピンホールの発生確率が増大し、ポケット径に対する収容部5の高さの比が小さくなるほどピンホールの発生確率が減少する。実施例3の包装体フィルムF1(容器用シート6)について、ピンホールの発生確率を、光の透過を目視にて確認することにより評価した。その結果を表2に示す。なお、実施例3の包装体フィルムF1の構成は後述する。
(Test Example 2: Formability test of container sheet 6)
In general, on the condition that the diameter (pocket diameter) of the
表2は、複数の収容部5を異なる高さで成形し、各収容部5における光の透過率を目視にて確認したものである。光の透過が確認できたポケットをピンホール有とカウントし、全体に対するピンホール発生率を示した。なお、成形に用いた金型のポケット径は15mmである。
Table 2 shows a case in which a plurality of
各収容部5のピンホール発生率を測定したところ、収容部5の高さを5.032mm以下とするとピンホール発生率が0%となることがわかった。したがって、上記の試験結果から、収容部5の直径が15mmの場合、収容部5の高さを5.032mm以下とするとピンホールの発生が認められず、好ましいことが示された。なお、収容部5の「高さ」とは、容器用シート6のバリア層4の平らな面(すなわち、収容部5が形成されていない面)からポケット最上面(天面)までの距離(図2中のH)を指す。また、「収容部5の直径(ポケット径)」とは、収容部5の開口部の内径(すなわち、図2中のL)を指す。このとき、収容部5の開口部は必ずしも真円形でなくとも良い。例えば、収容部5の開口部が矩形や楕円形である場合、「収容部5の直径(ポケット径)」とは、長手方向の内径を指すものである。
Measured pinhole occurrence rate of each
したがって、1種類以上の基材層2を含む包装体フィルムF1は、包装体Pの成形時、クラック及びピンホールが発生せず、好適であることが示された。また、収容部5の直径が15mmの場合、収容部5の高さを5.032mm以下とすると、ピンホールの発生が無く、好適であることが示された。
基材層2を含まない包装体Pを成形した場合、収容部5天面付近にクラックが発生した。
収容される固形製剤の形状、大きさにより、収容部5の直径を大きくすることで収容部5の高さを5.0mm以上に成形することは可能である。この場合、上記試験結果より、収容部5の直径に対する収容部5の高さの比は0.335を上限として成形されると好適である。
なお、収容部5の高さは、錠剤またはカプセル剤等の医薬品製剤の形状または大きさにより、適宜選択されれば特に限定されない。具体的には、例えば、(i)錠剤が長径15.1mmx短径8.0mmx高さ5.7mmの異形錠の場合、間口(収容部5の開口部)の大きさが長径24.0mmx短径22.0mm、高さが6.3mmの収容部(H/L=0.263)が挙げられ、また(ii)錠剤が直径9.6mmx高さ5.1mmの円形状の場合、間口の直径が19.6mm、高さが5.5mmの収容部(H/L=0.281)等が挙げられる。
Therefore, it was shown that the packaging body film F1 including one or more kinds of the base material layers 2 is suitable without generating cracks and pinholes when the packaging body P is formed. Moreover, when the diameter of the
When the package P that does not include the
Depending on the shape and size of the solid preparation to be accommodated, it is possible to increase the diameter of the
In addition, the height of the
((実施例3))
[包装体フィルムF1の構成]
吸着層1:ゼオライト(ユニオン昭和株式会社製、商品名:モレキュラーシーブ4A、有効細孔径:4Å)含有LDPE(東ソー株式会社製、商品名:ペトロセン202、厚さ:130μm)層の両面にLLDPE(株式会社プライムポリマー製、商品名:エボリュー(登録商標)SP2520)のスキン層が積層された2種3層
基材層2:PA(ポリアミド系樹脂)(株式会社興人製、商品名:ボニールW、厚さ:15μm)
アルミニウム箔3:合金アルミニウム箔(東洋アルミニウム株式会社製、商品名:スーパーホイル、厚さ:40μm)
バリア層4:PA(ポリアミド系樹脂)(株式会社興人製、商品名:ボニールW、厚さ:15μm)
((Example 3))
[Configuration of Packaging Film F1]
Adsorption layer 1: zeolite (made by Union Showa Co., Ltd., trade name: molecular sieve 4A, effective pore size: 4 mm) containing LDPE (made by Tosoh Corporation, trade name: Petrocene 202, thickness: 130 μm) on both sides of LLDPE ( Made of Prime Polymer Co., Ltd., trade name: Evolue (registered trademark) SP2520)
Aluminum foil 3: Alloy aluminum foil (manufactured by Toyo Aluminum Co., Ltd., trade name: super foil, thickness: 40 μm)
Barrier layer 4: PA (polyamide resin) (manufactured by Kojin Co., Ltd., trade name: Bonile W, thickness: 15 μm)
(試験例3:防湿性・吸湿性・ガス吸着性試験)
本発明の包装体Pは、保存環境下における水分、或いは固形製剤8中に含まれる水分により、加水分解が進行する成分を含む薬剤、1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸を含む薬剤に対して特に有用である。以下、1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸を含む固形製剤8に対して包装体Pを適用した場合について、説明する。
(Test Example 3: Dampproof / Hygroscopic / Gas Adsorbing Test)
The package P of the present invention contains 1-{[(α-isobutanoyloxyethoxy) carbonyl], a drug containing a component that is hydrolyzed by moisture in the storage environment or moisture contained in the
固形製剤8は、錠剤からなる徐放性の経口薬剤であって、有効成分として、化学式(1)で表される1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸を含む。1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸は、γ-アミノ酪酸(GABA)誘導体であるガバペンチン(化学式(2))のプロドラッグである。
The
1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸の持続放出経口薬剤は、薬理作用を有するガバペンチンが治療に有効だと知られている、又は今後そのことが発見されるいずれかの疾患又は障害に苦しむ患者に投与され得る。ガバペンチンが処方される症状、及びガバペンチンを含有する薬剤が有効である症状は、てんかん、うつ、不安、精神病、認知、統合失調症、失神発作、運動機能減少、頭蓋障害、神経変性障害、パニック、痛み{特に、神経障害性の痛み(例えばヘルペス後神経痛)、筋肉痛、及び骨格痛}、下肢静止不能症候群、ほてり、尿失禁、炎症性障害(すなわち関節症)、不眠症、胃腸障害、アルコール/コカイン中毒、エタノール離脱症候群、外陰病変、早漏、及びグルタミン酸作動性等である。 1-{[(α-Isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid sustained release oral drug is known or will be effective in the treatment of gabapentin having pharmacological action Can be administered to patients suffering from any disease or disorder in which is found. Symptoms for which gabapentin is prescribed and for which drugs containing gabapentin are effective include epilepsy, depression, anxiety, psychosis, cognition, schizophrenia, fainting, motor function decline, cranial disorders, neurodegenerative disorders, panic, Pain {especially neuropathic pain (eg postherpetic neuralgia), muscle pain, and skeletal pain}, restless leg syndrome, hot flashes, urinary incontinence, inflammatory disorders (ie arthropathy), insomnia, gastrointestinal disorders, alcohol / Cocaine poisoning, ethanol withdrawal syndrome, vulvar lesions, premature ejaculation, glutamatergic activity, etc.
当該薬剤は、上記疾患又は障害に対する予防措置としても、患者に投与され得る。それ故、当該薬剤は、てんかん、うつ、不安、精神病、失神発作、運動機能減少、頭蓋障害、神経変性障害、パニック、痛み(特に、神経障害性の痛み、及び筋肉痛、及び骨格痛)、炎症性障害(すなわち、関節症)、不眠症、胃腸障害、エタノール離脱症候群、早漏、及び外陰病変の傾向を有する患者へ、予防措置として投与され得る。 The drug can be administered to patients as a preventive measure against the above diseases or disorders. Therefore, the drug is used for epilepsy, depression, anxiety, psychosis, fainting, decreased motor function, cranial disorder, neurodegenerative disorder, panic, pain (especially neuropathic pain and muscle pain, and skeletal pain), It can be administered as a preventive measure to patients with a tendency for inflammatory disorders (ie arthropathy), insomnia, gastrointestinal disorders, ethanol withdrawal syndrome, premature ejaculation, and vulvar lesions.
従って、当該薬剤は、ある疾患又は障害の予防のために、同時に他の疾患又は障害を治療するために使用され得る(例えば、精神病の予防、胃腸障害の治療、神経障害性の痛みの予防、エタノール離脱症候群等の治療)。当該薬剤は、初期ウイルス性感染の間、抗ウイルス薬のような他の薬物との組み合わせにおいて使用され、神経病の障害の結果生じる事態を阻害又は低減し得る。 Thus, the medicament can be used for the prevention of certain diseases or disorders and at the same time to treat other diseases or disorders (e.g. prevention of psychosis, treatment of gastrointestinal disorders, prevention of neuropathic pain, Treatment of ethanol withdrawal syndrome, etc.). Such agents can be used in combination with other drugs, such as antiviral drugs, during early viral infections to inhibit or reduce events resulting from neurological disorders.
ガバペンチンの経口投与のための好適な用量範囲は、通常、約100mg/日~約3600mg/日であり、そして1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸あるいはそれらの医薬として許容される塩又は医薬として許容される溶媒和物は、ガバペンチンの等モル量を提供するように調節され得る。用量範囲は、当業者に知られる方法により容易に決定され得る。ある態様において、固形製剤中の1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸の量は約50mg~約800mg、ある態様において約100mg~約800mg、及びある態様において、約300mg~約700mgの範囲となる。また、用法としては、1日あたり1回~3回経口投与する。なお、投与量は症状、年令、性別等を考慮して個々の場合に応じて適宜決定されることが予想される。 Suitable dosage ranges for oral administration of gabapentin are usually about 100 mg / day to about 3600 mg / day and 1-{[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexane Acetic acid or a pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof can be adjusted to provide equimolar amounts of gabapentin. The dose range can be readily determined by methods known to those skilled in the art. In some embodiments, the amount of 1-{[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid in the solid formulation is about 50 mg to about 800 mg, in some embodiments about 100 mg to about 800 mg, and In some embodiments, it will be in the range of about 300 mg to about 700 mg. In addition, the dosage is orally administered 1 to 3 times per day. The dose is expected to be appropriately determined according to individual cases in consideration of symptoms, age, sex, and the like.
1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸は、水の存在下で加水分解され、それぞれ1molの水と1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸から、それぞれ1molのアセトアルデヒドと二酸化炭素とガバペンチンとイソブチルアルコールとが発生する。 1-{[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid is hydrolyzed in the presence of water to give 1 mol of water and 1-{[(α-isobutanoyloxy, respectively). 1 mol of acetaldehyde, carbon dioxide, gabapentin and isobutyl alcohol are generated from ethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid, respectively.
固形製剤8が大気に曝されている場合、または収容部5内に水が残留していた場合、さらに固形製剤8の内部に水が含有されている場合等、固形製剤8の周辺又は内部に水が存在する限り、1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸は、加水分解により、アセトアルデヒドと二酸化炭素とガバペンチンとイソブチルアルコールを生成する。このとき、1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸の加水分解反応で使われた1molの水と同量の水がガバペンチンの脱水反応で生成されるため、この脱水反応により生成された水が、新たな加水分解反応を進行させる。
When the
固形製剤8は、有効成分である1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸のほか、添加剤として放出速度制御高分子、賦形剤、希釈剤、流動化剤、滑沢剤、増粘抑制剤、界面活性剤、緩衝液、染料、湿潤剤、乳化剤、pH緩衝剤、安定剤、増粘剤、崩壊剤、及び着色剤を含む。添加剤は1種または2種以上組み合わせて適宜適量添加することができる。
The
放出速度制御高分子は、グリセリルモノステアレート、グリセリルベヘネート、グリセリルパルミトステアレート、ラウロイルマクロゴールグリセリド、ステアロイルマクロゴールグリセリド、又は上述のいずれかの組み合わせの如きグリセリルエステルである。ある態様において、当該放出速度改良ポリマーは、グリセリルベヘネートである。他の脂肪、及び/又はワックス放出速度改良ポリマーは、ラウリルアルコール、ミリスチルアルコール、ステアリルアルコール、セチルアルコール、セトステアリルアルコール、パルミトイルアルコール、ouricuryワックス、硬化植物油、カンデリラワックス、エスパルトワックス、ステアリン酸、パラフィンワックス、蜜ろう、グリコワックス、キャスターワックス、及びカルナバワックスを含む。 The release rate controlling polymer is a glyceryl ester such as glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, lauroyl macrogol glyceride, stearoyl macrogol glyceride, or any combination of the above. In certain embodiments, the release rate improving polymer is glyceryl behenate. Other fat and / or wax release rate improving polymers include lauryl alcohol, myristyl alcohol, stearyl alcohol, cetyl alcohol, cetostearyl alcohol, palmitoyl alcohol, ouricury wax, hydrogenated vegetable oil, candelilla wax, esparto wax, stearic acid, Includes paraffin wax, beeswax, glycowax, castor wax, and carnauba wax.
賦形剤は、でんぷん、糖、ゼラチン、モルト、米、小麦粉、チョーク、シリカゲル、ステアリン酸ナトリウム、グリセロールモノステアレート、滑石、塩化ナトリウム、グリセロール、プロピレングリコール、水、エタノールなどを含む。
希釈剤は、薬剤を圧縮のため実用的な大きさとするために添加され得、容積を増大し得る。有用な希釈剤の例は、第2リン酸カルシウム、第2リン酸カルシウムジハイドライド、硫酸カルシウム、第3リン酸カルシウム、乳糖、微晶性セルロ-スを含むセルロース、カオリン、マンニトール、塩化ナトリウム、乾燥でんぷん、アルファでんぷん、圧縮性の糖、マンニトール、及び上述のいずれかの組み合わせを含む。ある態様において、単一の希釈剤は、第2リン酸カルシウム、及び微晶性セルロ-スから選択される。当該希釈剤が第2リン酸カルシウムである態様において、薬剤は、約30重量%~約50重量%、及びある態様においては約35重量%~約45重量%の範囲である希釈剤の量を含み得る。当該希釈剤が微晶性セルロースである態様において、薬剤は、約5重量%~約20重量%、及びある態様においては約10重量%~約16重量%の範囲である希釈剤の量を含むことが出来る。
Excipients include starch, sugar, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, glycerol, propylene glycol, water, ethanol and the like.
Diluents can be added to increase the volume of the drug to make it practical for compression. Examples of useful diluents are dicalcium phosphate, dicalcium phosphate dihydride, calcium sulfate, tricalcium phosphate, lactose, cellulose containing microcrystalline cellulose, kaolin, mannitol, sodium chloride, dried starch, alpha starch, Compressible sugar, mannitol, and combinations of any of the above. In some embodiments, the single diluent is selected from dicalcium phosphate and microcrystalline cellulose. In embodiments where the diluent is dicalcium phosphate, the agent may include an amount of diluent that ranges from about 30 wt% to about 50 wt%, and in some embodiments from about 35 wt% to about 45 wt%. . In embodiments where the diluent is microcrystalline cellulose, the agent comprises an amount of diluent that ranges from about 5 wt% to about 20 wt%, and in some embodiments from about 10 wt% to about 16 wt%. I can do it.
流動化剤は、本発明の薬剤中に含まれ、製造、膜形成、及び/又は乾燥の間、付着効果を低減する。有用な流動化剤の例は、滑石、ステアリン酸マグネシウム、グリセリルモノステアレート、コロイド状シリコンジオキシド、沈降シリコンジオキシド、上述のいずれかの組み合わせである。ある態様において、流動化剤は、コロイド状シリコンジオキシドである。薬剤は、約2重量%未満の流動化剤、ある態様において、約1重量%未満の流動化剤を含むことが出来る。 A fluidizing agent is included in the drug of the present invention to reduce the adhesion effect during manufacture, film formation, and / or drying. Examples of useful fluidizing agents are talc, magnesium stearate, glyceryl monostearate, colloidal silicon dioxide, precipitated silicon dioxide, any combination of the above. In certain embodiments, the fluidizing agent is colloidal silicon dioxide. The medicament may comprise less than about 2% by weight fluidizing agent, and in certain embodiments, less than about 1% by weight fluidizing agent.
滑沢剤、及び増粘抑制剤は、加工に役立つために本発明の薬剤中に含まれ得る。有用な滑沢剤、及び/又は増粘抑制剤の例は、ステアリン酸カルシウム、グリセリルベヘネート、グリセリルモノステアレート、ステアリン酸マグネシウム、鉱油、ポリエチレングリコール、ソジウムステアリルフマレート、ラウリル硫酸ナトリウム、ドデシル硫酸ナトリウム、ステアリン酸、滑石、硬化植物油、ステアリン酸亜鉛、及び上述のいずれかの組み合わせである。ある態様において、当該滑沢剤は、グリセリルモノステアレートである。ある態様において、滑沢剤は、ステアリン酸マグネシウムである。薬剤は、約1重量%~約13重量%の、ある態様において、約4重量%~約10重量%の範囲の滑沢剤、及び/又は増粘抑制剤を含むことが出来る。 Lubricants and thickening inhibitors can be included in the agents of the present invention to aid in processing. Examples of useful lubricants and / or thickening inhibitors are calcium stearate, glyceryl behenate, glyceryl monostearate, magnesium stearate, mineral oil, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulfate, dodecyl Sodium sulfate, stearic acid, talc, hydrogenated vegetable oil, zinc stearate, and any combination of the above. In certain embodiments, the lubricant is glyceryl monostearate. In certain embodiments, the lubricant is magnesium stearate. The medicament may comprise from about 1% to about 13% by weight, in some embodiments, from about 4% to about 10% by weight lubricants and / or thickening inhibitors.
本発明の薬剤において有用な界面活性剤の例は、医薬として許容される、アニオン性界面活性剤、カチオン性界面活性剤、両性{両親媒性(amphiphatic)/両親媒性(amphiphilic)}界面活性剤、非イオン性界面活性剤、ポリエチレングリコールエステル又はエーテル、及び上述のいずれかの組み合わせを含む。好適な医薬として許容されるアニオン性界面活性剤は、1価アルキルカルボキシレート、アシルラクチレート、アルキルエーテルカルボキシレート、N-アシルサルコシネート、多価アルキルカルボネート、N-アシルグルタメート、脂肪酸-ポリペプチド凝縮物、硫酸エステル、ラウリル硫酸ナトリウム及びドデシル硫酸ナトリウムの如きアルキルスルフェイト、エトキシル化アルキルスルフェイト、ドキュセートナトリウム及びジオクチルソジウムスクシネートの如きエステル結合スルホネート、アルファオレフィンスルホネート、又はリン酸化エトキシル化アルコールを含む。
本実施形態の固形製剤8は、成形された錠剤からなるが、カプセル剤であっても良い。
Examples of surfactants useful in the agents of the present invention include pharmaceutically acceptable anionic surfactants, cationic surfactants, amphoteric {amphiphilic / amphiphilic} surfactants. Agents, nonionic surfactants, polyethylene glycol esters or ethers, and combinations of any of the above. Suitable pharmaceutically acceptable anionic surfactants are monovalent alkyl carboxylates, acyl lactylates, alkyl ether carboxylates, N-acyl sarcosinates, polyvalent alkyl carbonates, N-acyl glutamates, fatty acid-polys. Peptide condensates, sulfates, alkyl sulfates such as sodium lauryl sulfate and sodium dodecyl sulfate, ethoxylated alkyl sulfates, ester-linked sulfonates such as sodium docusate and dioctyl sodium succinate, alpha olefin sulfonates, or ethoxylated phosphorylates Containing alcohol.
The
1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸を含む固形製剤8に対して、本発明の包装体Pを適用した際の効果を評価した。
1 − {[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid was evaluated for the effect when the package P of the present invention was applied to the
((製剤例))
特表2008-518971号明細書に記載された方法に準じて、1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸(300mg)を含む655mgの錠剤からなる固形製剤8を製造した。
((Formulation example))
According to the method described in the specification of JP-T-2008-518971, it consists of a 655 mg tablet containing 1-{[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid (300 mg).
1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸(有効成分)、リン酸水素カルシウム(希釈剤)、グリセリン脂肪酸エステル(放出制御高分子)、タルク(流動化剤)、軽質無水ケイ酸(流動化剤)、ラウリル硫酸ナトリウム(界面活性剤)、ステアリン酸マグネシウム(滑沢剤)を混合して圧縮し、総重量655.0mgの錠剤を得た。
錠剤1錠あたりの組成は、1-{[(α-イソブタノイルオキシエトキシ)カルボニル]アミノメチル}-1-シクロヘキサン酢酸300mg、リン酸水素カルシウム259.1mg、グリセリン脂肪酸エステル30.05mg、タルク40.0mg、軽質無水ケイ酸2.7mg、ラウリル硫酸ナトリウム12.0mg、ステアリン酸マグネシウム11.15mgであった。
1-{[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid (active ingredient), calcium hydrogen phosphate (diluent), glycerin fatty acid ester (release controlling polymer), talc (flow) Agent), light anhydrous silicic acid (fluidizing agent), sodium lauryl sulfate (surfactant), and magnesium stearate (lubricant) were mixed and compressed to obtain tablets having a total weight of 655.0 mg.
The composition per tablet was as follows: 1-{[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid 300 mg, calcium hydrogen phosphate 259.1 mg, glycerin fatty acid ester 30.05 mg,
((実施例1))
上記製剤例で得られた固形製剤8を、以下の構成の包装体フィルムF1によって形成した容器用シート6と、アルミニウムからなる蓋材シート7を接着して封止することにより、包装体Pを得た。なお、実施例1の容器用シート6を構成する包装体フィルムF1の構成は、上述した実施例1と同様であるため、その説明を省略する。
((Example 1))
The
((比較例1))
上記製剤例で得られた固形製剤8を、吸着層1を備えない以下の構成の包装体フィルムF1によって形成した容器用シート6と、アルミニウムからなる蓋材シート7を接着して封止することにより、包装体Pを得た。
[包装体フィルムの構成]
吸着層1:なし
基材層2:PVC(ポリ塩化ビニル)(厚さ:60μm)
アルミニウム箔3:純アルミニウム箔(厚さ:45μm)
バリア層4:延伸ポリアミド樹脂(厚さ:25μm)
((Comparative Example 1))
The
[Configuration of packaging film]
Adsorption layer 1: None Base material layer 2: PVC (polyvinyl chloride) (thickness: 60 μm)
Aluminum foil 3: Pure aluminum foil (thickness: 45 μm)
Barrier layer 4: Stretched polyamide resin (thickness: 25 μm)
((比較例2))
上記製剤例で得られた固形製剤8を、以下の構成の包装体フィルムF1によって形成した容器用シート6と、アルミニウムからなる蓋材シート7を接着して封止することにより、包装体Pを得た。
[包装体フィルムの構成]
吸着層1:酸化カルシウム含有低密度ポリエチレン
(ポリエチレンに対する酸化カルシウム量:30wt%)含有(厚さ:40μm)
基材層2:EAA(エチレン-アクリル酸共重合体)(厚さ:10μm)
アルミニウム箔3:純アルミニウム箔(厚さ:45μm)
バリア層4:延伸ポリアミド樹脂(厚さ:25μm)
((Comparative Example 2))
The
[Configuration of packaging film]
Adsorption layer 1: low density polyethylene containing calcium oxide (calcium oxide amount relative to polyethylene: 30 wt%) (thickness: 40 μm)
Base material layer 2: EAA (ethylene-acrylic acid copolymer) (thickness: 10 μm)
Aluminum foil 3: Pure aluminum foil (thickness: 45 μm)
Barrier layer 4: Stretched polyamide resin (thickness: 25 μm)
上記実施例1、比較例1及び比較例2において、固体製剤8に対する包装体Pに含有される有効成分の安定化効果を調べるため、色差測定による外観相対比較を行った。図3乃至図6に、各温度における色差測定結果のグラフ図を示す。なお、グラフ中のΔEは、製造直後の固形製剤8と、所定温度(図3:50℃、図4:40℃、図5:30℃、図6:25℃)で保存後の固形製剤8との色差ΔEを色差計によって測定した値を示している。
In the above Example 1, Comparative Example 1 and Comparative Example 2, in order to examine the stabilizing effect of the active ingredient contained in the package P with respect to the
なお、本明細書において、「着色」とは、外観上、白色から白色以外の色を呈することを意味する。
実施例1、比較例1及び2で得られた固形製剤8の包装体Pをサンプルとして、以下の各試験を行った。
In the present specification, “coloring” means that a color other than white is exhibited in appearance.
The following tests were performed using the package P of the
所定温度において、製造後冷所にて保管した固形製剤8を対照サンプルとし、実施例1、比較例1及び2の各サンプルをそれぞれ50℃、40℃、30℃、25℃(いずれも相対湿度75%)で保存したものを保存後サンプルとした。各包装体Pに包装されていた固形製剤8を取り出して、色差計(CM-3500d、コニカミノルタ製)により、対照サンプルと保存後サンプルとの色差ΔEを測定して外観を評価した。
The
図3では、50℃で保存した時、実施例1は比較例1及び2と比較して、固形製剤8の着色の程度が小さいことが示されている。吸着層1を備えない比較例1と比較して、実施例1の色差ΔEは、3日後の時点で約3分の一程度であり、実施例1の包装体Pにより、固形製剤8の着色が大きく抑制されていることが示されている。さらに、実施例1は、酸化カルシウムを吸着層1に含む比較例2の包装体Pよりも、固形製剤8の着色を抑制することができることが示された。
FIG. 3 shows that when stored at 50 ° C., Example 1 has a lower degree of coloring of
図4では、40℃で保存した時もまた、実施例1は比較例1及び2と比較して固形製剤8の着色の程度が小さいことが示された。比較例1のように、吸着層1を備えない場合、1か月後ではΔEが約32という高い値を示したが、酸化カルシウムを吸着層1に含有する比較例2、及び本実施例1は約1程度であった。
そして、さらに保存期間を延長した3か月経過後は、実施例1のΔEは約12程度であったが、比較例2のΔEは約22であり、長期保存後は、ΔEの差が顕著になっていた。したがって本色差測定により、本発明の包装体Pが着色を効果的に抑制することが示された。
In FIG. 4, Example 1 showed that the degree of coloring of the
Further, after 3 months of extending the storage period, ΔE of Example 1 was about 12, but ΔE of Comparative Example 2 was about 22, and the difference in ΔE was remarkable after long-term storage. It was. Therefore, it was shown by this color difference measurement that the package P of the present invention effectively suppresses coloring.
図5では、30℃で保存した時、実施例1と比較例1とは僅差ではあるが、実施例1の方がΔEが小さいことが示されている。そして、実施例1は、保存温度が30℃の時、6か月間の保存期間を通して、常にΔEが1未満であり、着色の程度は極めて小さく、固形製剤8の保存に適していることが確認された。
FIG. 5 shows that Example 1 and Comparative Example 1 are slightly different when stored at 30 ° C., but ΔE is smaller in Example 1. In Example 1, when the storage temperature is 30 ° C., ΔE is always less than 1 throughout the storage period of 6 months, the degree of coloring is extremely small, and it is confirmed that it is suitable for storage of the
図6では、25℃で保存した時、6か月後、実施例1は、酸化カルシウムを吸着層1に含む比較例2と比較して、ΔEが小さい値で保持されていることが示されている。25℃の場合においてもまた、6か月間が経過した時点では着色の程度が小さいままであることが確認された。
In FIG. 6, when stored at 25 ° C., after 6 months, Example 1 shows that ΔE is held at a small value as compared with Comparative Example 2 in which calcium oxide is contained in the
したがって、上記色差測定の結果より、本発明の包装体Pのように、固形製剤8が収容される側にゼオライトを含有した吸着層1を備えた包装体Pとすることにより、固形製剤8の着色が効果的に防止されることが明らかになった。
Therefore, from the result of the above color difference measurement, by using the package P including the
なお、色差測定では、実施例1(吸着層1の厚さが50μm)の包装体Pを評価したが、上述の実施例2の包装体P(ただし、吸着層1の厚さを130μmとしたものを評価した。吸着層1以外の層構成は、上述の実施例2の構成と同様である。)の色差測定を行ったところ、両者はほぼ同様の色差ΔEを示した。
In the color difference measurement, the packaging body P of Example 1 (the thickness of the
上記結果は、比較例1のように、外部からの水等の侵入を防止するだけの構成ではなく、包装時に収容部5内に含まれていた水を吸着層1によって吸収することにより、有効成分を安定化できることを示している。
The above results are not limited to the configuration of preventing intrusion of water or the like from the outside as in Comparative Example 1, but are effective by absorbing the water contained in the
さらに、上記結果より、包装体Pの構成において、ゼオライトを含む吸着層1を備えなかった場合、保存温度によっては十分な有効成分の安定化を図ることが難しいが、包装体Pの容器用シート6において、固形製剤8を収容する側の面をゼオライトが含まれた吸着層1で構成することにより、有効成分を安定化することができ、加水分解の進行を効果的に抑制できることがわかった。
この結果は、水のみを吸着する酸化カルシウムと比較して、ゼオライトが水だけでなく、他の気体分子(アルデヒド、CO2等)に対する吸着能を備えていることに起因すると推測される。
Furthermore, from the above results, in the configuration of the package P, when the
This result is presumed to be due to the fact that zeolite has an ability to adsorb not only water but also other gas molecules (aldehyde, CO 2, etc.) as compared with calcium oxide that adsorbs only water.
(試験例4:口腔内崩壊錠の溶出速度)
上記実施例1、比較例1及び2の包装体Pを用いて、水溶性の薬剤成分を含む口腔内崩壊錠に対する本発明の包装体Pの効果を評価した。
なお、評価した実施例1、比較例1及び2の包装体Pの構成は上記の構成と同様であるため、その説明を省略する。
(Test Example 4: Dissolution rate of orally disintegrating tablets)
Using the package P of Example 1 and Comparative Examples 1 and 2, the effect of the package P of the present invention on the orally disintegrating tablet containing a water-soluble drug component was evaluated.
In addition, since the structure of the package P of evaluated Example 1 and Comparative Examples 1 and 2 is the same as said structure, the description is abbreviate | omitted.
((製剤例))
国際公開2006-070735号パンフレットに記載された方法に準じて、コハク酸ソリフェナシンを含む150mgの口腔内崩壊錠である固形製剤8を製造した。
((Formulation example))
According to the method described in the pamphlet of International Publication No. 2006-070735,
結晶セルロース(粒)に、コハク酸ソリフェナシンを被覆した粒子を得た後、該粒子に、マンニトール(賦形剤)を加え、マルトース(結合剤)水溶液を噴霧し、被覆および造粒した。該造粒物にステアリン酸マグネシウム(滑沢剤)を混合後、ロータリー打錠機を用いて錠剤を製した。つぎに、該錠剤を、加湿乾燥機を用いて加湿乾燥を行い、1錠あたり150mgの口腔内崩壊錠を得た。 After obtaining particles in which crystalline cellulose (grains) was coated with solifenacin succinate, mannitol (excipient) was added to the particles, and an aqueous maltose (binder) solution was sprayed to coat and granulate. After mixing magnesium stearate (lubricant) into the granulated product, tablets were produced using a rotary tableting machine. Next, the tablets were humidified and dried using a humidifying dryer to obtain 150 mg of orally disintegrating tablets per tablet.
実施例1、比較例1及び2の包装体Pによって、口腔内崩壊錠を包装し、それぞれ3か月間(実施例1-1、比較例1-1、比較例2-1)及び6か月間(実施例1-2、比較例1-2)保存した(保存条件:40℃、相対湿度75%、暗所)。
所定の保存期間後の口腔内崩壊錠の溶出度(0,30,45分経過後の値を測定)を図7に示す。溶出試験はpH6.8リン酸塩緩衝液900mLを用い,パドル法毎分50回転にて実施した。
Orally disintegrating tablets are packaged by the package P of Example 1 and Comparative Examples 1 and 2 for 3 months (Example 1-1, Comparative Example 1-1, Comparative Example 2-1) and 6 months, respectively. (Example 1-2, Comparative Example 1-2) Stored (storage conditions: 40 ° C., relative humidity 75%, dark place).
FIG. 7 shows the degree of dissolution of the orally disintegrating tablet after a predetermined storage period (measured after 0, 30, 45 minutes). The dissolution test was carried out at 900 rpm with a paddle method using 900 mL of pH 6.8 phosphate buffer.
その結果、保存期間を3か月としたサンプルでは、30分経過後の溶出度に有意な差が観測された。実施例1-1では溶出度が99%、比較例1-1では81%、比較例2-1では98%であり、実施例1の包装体Pに包装された口腔内崩壊錠は、吸着層1に酸化カルシウムを含む比較例2-1の包装体Pと同様、高い溶出性を保持することが示された。
As a result, in the sample with a storage period of 3 months, a significant difference was observed in the dissolution after 30 minutes. The dissolution rate was 99% in Example 1-1, 81% in Comparative Example 1-1, and 98% in Comparative Example 2-1, and the orally disintegrating tablet packaged in the package P of Example 1 was adsorbed. As with the package P of Comparative Example 2-1, in which
また、保存期間を6か月としたサンプルでもまた、30分経過後の溶出度に大きな差が観測された。実施例1-2では溶出度が92%、比較例1-2では82%であり、実施例1の包装体Pに包装された口腔内崩壊錠は、高い溶出性を保持することが示された。 Moreover, a large difference was observed in the elution degree after 30 minutes even in the sample with a storage period of 6 months. In Example 1-2, the dissolution rate was 92%, and in Comparative Example 1-2, 82%. It was shown that the orally disintegrating tablet packaged in the package P of Example 1 retains high dissolution properties. It was.
口腔内崩壊錠は、錠剤が口腔内において唾液又は少量の水で崩壊する錠剤であり、口腔内では速やかに溶解(崩壊)することが求められる。一般に、口腔内崩壊錠は保存状態が好ましくないと、溶出の遅延が起こり、短時間で溶解(崩壊)しにくくなる。これに対し、本発明の包装体Pによって、口腔内崩壊錠の溶出遅延が抑制され、短時間で高い溶出性を備えることが上記評価によって示された。この結果は、本発明の包装体Pに備えられた吸着層1が、水等を効果的に吸着するため、吸着層1の口腔内崩壊錠の安定化に寄与していると推測される。
Orally disintegrating tablets are tablets that disintegrate in the oral cavity with saliva or a small amount of water, and are required to dissolve (disintegrate) rapidly in the oral cavity. In general, when the orally disintegrating tablet is not preferably stored, the dissolution is delayed and it is difficult to dissolve (disintegrate) in a short time. On the other hand, it was shown by the said evaluation that the dissolution delay of an orally disintegrating tablet was suppressed by the package P of this invention, and it has high dissolution property in a short time. This result is presumed that the
(他の実施形態)
また、本発明の包装体Pに用いられる包装体フィルムは、上記の包装体フィルムF1の構成に限定されるものではない。包装体フィルムF1では、基材層として、基材層2のみを設けた構成としているが、図8に示す包装体フィルムF2のように、基材層として、複数の基材層(主基材層2a,副基材層2b)を備えた構成であっても良い。
(Other embodiments)
Moreover, the packaging body film used for the packaging body P of this invention is not limited to the structure of said packaging body film F1. In the packaging film F1, only the
図8は、本発明の他の実施形態に係る包装体フィルムF2の概略断面図である。
吸着層1、アルミニウム箔3、バリア層4の構成及び作用は上記包装体フィルムF1のものと同等であるため、その説明を省略する。
主基材層2a及び副基材層2bは、上記基材層2と同様、包装体フィルムF2に適度な剛性及び成形性を付与するために備えられる。そして、主基材層2a及び副基材層2bは上記基材層2と同様の材料で構成される。
FIG. 8 is a schematic cross-sectional view of a packaging body film F2 according to another embodiment of the present invention.
Since the structure and action of the
The main
なお、上記薬物の配合量は、医薬的に予防または治療上有効な量であれば特に制限されないが、通常1日当たり10ng以上5000mg以下、他の態様として、500μg以上1000mg以下、更なる態様として、1mg以上約100mg以下の成人投与レベルで患者に投与される。また、配合割合は、通常薬物の種類、用途(適応症)、年齢(または体重)に応じ適宜選択されるが、治療学的に有効な量あるいは予防学的に有効な量であれば特に制限されない。
The compounding amount of the drug is not particularly limited as long as it is a pharmaceutically preventive or therapeutically effective amount, but is usually 10 ng or more and 5000 mg or less per day, and as another embodiment, 500 μg or more and 1000 mg or less, Administered to patients at an adult dosage level of 1 mg to about 100 mg. In addition, the compounding ratio is usually appropriately selected according to the type, use (indication), and age (or body weight) of the drug, but is particularly limited if it is a therapeutically effective amount or a prophylactically effective amount. Not.
Claims (5)
該包装体は、前記固形製剤を収容する凹状の収容部が形成された容器用シートと、
前記固形製剤を封止する気密性を備えた蓋材シートと、を備え、
前記容器用シートは、吸着層と、樹脂によって構成される少なくとも一層以上の基材層と、アルミニウム箔と、バリア層とが積層された包装体フィルムからなり、
前記吸着層は、前記基材層と積層されると共に前記固形製剤が収容される側に配設され、少なくともゼオライトを含有してなることを特徴とする包装体。 A package containing a solid preparation containing solifenacin succinate or 1-{[(α-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-cyclohexaneacetic acid,
The package body is a container sheet in which a concave housing portion for housing the solid preparation is formed;
A lid sheet with airtightness for sealing the solid preparation,
The container sheet is composed of a packaging film in which an adsorption layer, at least one base material layer composed of a resin, an aluminum foil, and a barrier layer are laminated,
The said adsorption layer is laminated | stacked with the said base material layer, and is arrange | positioned by the side in which the said solid formulation is accommodated, The package body characterized by including a zeolite at least.
The package according to any one of claims 1 to 4, wherein the effective pore diameter of the zeolite is 3 mm or more.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11821914.6A EP2612827A4 (en) | 2010-09-01 | 2011-09-01 | PACKAGING |
| JP2012531957A JP5936542B2 (en) | 2010-09-01 | 2011-09-01 | Package |
| US13/819,133 US20130153459A1 (en) | 2010-09-01 | 2011-09-01 | Package |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010-195976 | 2010-09-01 | ||
| JP2010195976 | 2010-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012029899A1 true WO2012029899A1 (en) | 2012-03-08 |
Family
ID=45772974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2011/069881 Ceased WO2012029899A1 (en) | 2010-09-01 | 2011-09-01 | Package |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130153459A1 (en) |
| EP (1) | EP2612827A4 (en) |
| JP (1) | JP5936542B2 (en) |
| WO (1) | WO2012029899A1 (en) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013128608A1 (en) * | 2012-03-01 | 2013-09-06 | 共同印刷株式会社 | Medicinal product package |
| WO2013140821A1 (en) * | 2012-03-23 | 2013-09-26 | 第一三共株式会社 | Layered body for ptp or blister pack, and ptp or blister pack |
| JP2014233887A (en) * | 2013-05-31 | 2014-12-15 | 大日本印刷株式会社 | Medicine packing body |
| JP2015006918A (en) * | 2013-05-31 | 2015-01-15 | 大日本印刷株式会社 | Ptp blister sheet and ptp blister package comprising the same |
| JP2015091721A (en) * | 2013-09-30 | 2015-05-14 | 大日本印刷株式会社 | Hygroscopic packaging |
| JP2015091720A (en) * | 2013-09-30 | 2015-05-14 | 大日本印刷株式会社 | Hygroscopic easily peelable packaging |
| WO2015194645A1 (en) * | 2014-06-18 | 2015-12-23 | 共同印刷株式会社 | Absorbent layer for blister packs, laminate comprising same, and blister pack using said laminate |
| WO2015194644A1 (en) * | 2014-06-18 | 2015-12-23 | アステラス製薬株式会社 | Laminate for blister pack and blister pack using same |
| WO2016063987A1 (en) * | 2014-10-23 | 2016-04-28 | 共同印刷株式会社 | Laminate for blister pack, blister pack using same, blister pack package, and method for manufacturing same |
| WO2016204293A1 (en) * | 2015-06-18 | 2016-12-22 | 共同印刷株式会社 | Laminate for use in blister pack, and blister pack using same |
| WO2016204291A1 (en) * | 2015-06-18 | 2016-12-22 | 共同印刷株式会社 | Laminate for use in blister pack, and blister pack using same |
| WO2016204292A1 (en) * | 2015-06-18 | 2016-12-22 | 共同印刷株式会社 | Laminate for use in blister pack, and blister pack using same |
| US10239680B2 (en) * | 2010-09-01 | 2019-03-26 | Kyodo Printing Co., Ltd. | Blister package containing the laminated sheet and container |
| WO2019111960A1 (en) * | 2017-12-06 | 2019-06-13 | 大原薬品工業株式会社 | Amorphous-solifenacin drug package |
| JP2020157559A (en) * | 2019-03-26 | 2020-10-01 | 大日本印刷株式会社 | Deodorant laminate |
| JP2022062541A (en) * | 2020-10-08 | 2022-04-20 | 共同印刷株式会社 | Transparent moisture-absorbing film |
| JP2022092786A (en) * | 2020-12-11 | 2022-06-23 | 株式会社メタルカラー | Aluminum foil laminate for ptp packaging |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6801970B2 (en) * | 2016-03-15 | 2020-12-16 | スタープラスチック工業株式会社 | Package |
| US10842022B2 (en) * | 2017-09-15 | 2020-11-17 | Ocella Inc | Multilayered flexible electronics platform |
| KR101933448B1 (en) * | 2017-09-27 | 2018-12-28 | 백종영 | Urethane adhesive composite for pharmaceutical paper and pharmaceutical paper including the same |
| CA3110091A1 (en) * | 2018-09-20 | 2020-03-26 | Csp Technologies, Inc. | One or more blister packages containing active material and methods of making and using same |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006070735A1 (en) | 2004-12-27 | 2006-07-06 | Astellas Pharma Inc. | Stable granular pharmaceutical composition of solifenacin or its salt |
| JP2006327690A (en) | 2005-04-26 | 2006-12-07 | Kyodo Printing Co Ltd | Film for PTP or blister pack and packaging container for PTP or blister pack |
| JP2006346888A (en) * | 2005-06-13 | 2006-12-28 | Kyodo Printing Co Ltd | Selective hygroscopic film and multilayer film |
| JP3983131B2 (en) | 2002-07-30 | 2007-09-26 | 東洋アルミニウム株式会社 | Package |
| JP2008518971A (en) | 2004-11-04 | 2008-06-05 | ゼノポート,インコーポレイティド | Gabapentin prodrug sustained release oral drug |
| JP2010504252A (en) * | 2006-09-25 | 2010-02-12 | 武田薬品工業株式会社 | Pharmaceutical package |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE467825B (en) * | 1991-01-22 | 1992-09-21 | Neste Oy | SETTING OUT OF PLASTIC MATERIALS ELIMINATE SMELLING / TASTEING OBJECTS |
| GB0015043D0 (en) * | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| JP3919503B2 (en) * | 2000-11-13 | 2007-05-30 | 共同印刷株式会社 | Desiccant-mixed film and manufacturing method thereof |
| DE10343668A1 (en) * | 2003-09-18 | 2005-04-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | pharmaceutical blister |
| EP1849708B1 (en) * | 2005-02-07 | 2011-04-06 | Kyodo Printing Co., Ltd. | Packaging bag with moisture absorption indicator function and drying agent |
| EP1733872A1 (en) * | 2005-06-15 | 2006-12-20 | Alcan Technology & Management Ltd. | Cold formable laminate |
| JP5241503B2 (en) * | 2006-10-25 | 2013-07-17 | 第一三共株式会社 | Packaging material |
| JP2009297936A (en) * | 2008-06-11 | 2009-12-24 | Toppan Printing Co Ltd | Moistureproof packaging material |
| KR20110124338A (en) * | 2009-03-02 | 2011-11-16 | 아스텔라스세이야쿠 가부시키가이샤 | Package of solid preparation |
| JP2011042371A (en) * | 2009-08-19 | 2011-03-03 | Taketomo:Kk | Ptp package |
| PL2353573T3 (en) * | 2010-02-10 | 2013-01-31 | E Pharma Trento S P A | New strengthened blister pack |
-
2011
- 2011-09-01 JP JP2012531957A patent/JP5936542B2/en not_active Expired - Fee Related
- 2011-09-01 EP EP11821914.6A patent/EP2612827A4/en not_active Withdrawn
- 2011-09-01 US US13/819,133 patent/US20130153459A1/en not_active Abandoned
- 2011-09-01 WO PCT/JP2011/069881 patent/WO2012029899A1/en not_active Ceased
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3983131B2 (en) | 2002-07-30 | 2007-09-26 | 東洋アルミニウム株式会社 | Package |
| JP2008518971A (en) | 2004-11-04 | 2008-06-05 | ゼノポート,インコーポレイティド | Gabapentin prodrug sustained release oral drug |
| WO2006070735A1 (en) | 2004-12-27 | 2006-07-06 | Astellas Pharma Inc. | Stable granular pharmaceutical composition of solifenacin or its salt |
| JP2006327690A (en) | 2005-04-26 | 2006-12-07 | Kyodo Printing Co Ltd | Film for PTP or blister pack and packaging container for PTP or blister pack |
| JP2006346888A (en) * | 2005-06-13 | 2006-12-28 | Kyodo Printing Co Ltd | Selective hygroscopic film and multilayer film |
| JP2010504252A (en) * | 2006-09-25 | 2010-02-12 | 武田薬品工業株式会社 | Pharmaceutical package |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP2612827A4 |
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10239680B2 (en) * | 2010-09-01 | 2019-03-26 | Kyodo Printing Co., Ltd. | Blister package containing the laminated sheet and container |
| WO2013128608A1 (en) * | 2012-03-01 | 2013-09-06 | 共同印刷株式会社 | Medicinal product package |
| JPWO2013128608A1 (en) * | 2012-03-01 | 2015-07-30 | 共同印刷株式会社 | Pharmaceutical package |
| JPWO2013140821A1 (en) * | 2012-03-23 | 2015-08-03 | 第一三共株式会社 | Laminate for PTP or blister pack and PTP or blister pack |
| WO2013140821A1 (en) * | 2012-03-23 | 2013-09-26 | 第一三共株式会社 | Layered body for ptp or blister pack, and ptp or blister pack |
| CN104169187A (en) * | 2012-03-23 | 2014-11-26 | 第一三共株式会社 | Laminate for extrusion or blister packaging, and extrusion or blister packaging |
| JP2014233887A (en) * | 2013-05-31 | 2014-12-15 | 大日本印刷株式会社 | Medicine packing body |
| JP2015006918A (en) * | 2013-05-31 | 2015-01-15 | 大日本印刷株式会社 | Ptp blister sheet and ptp blister package comprising the same |
| JP2015091720A (en) * | 2013-09-30 | 2015-05-14 | 大日本印刷株式会社 | Hygroscopic easily peelable packaging |
| JP2019031337A (en) * | 2013-09-30 | 2019-02-28 | 大日本印刷株式会社 | Hygroscopic easily peelable packaging |
| JP2015091721A (en) * | 2013-09-30 | 2015-05-14 | 大日本印刷株式会社 | Hygroscopic packaging |
| WO2015194645A1 (en) * | 2014-06-18 | 2015-12-23 | 共同印刷株式会社 | Absorbent layer for blister packs, laminate comprising same, and blister pack using said laminate |
| WO2015194644A1 (en) * | 2014-06-18 | 2015-12-23 | アステラス製薬株式会社 | Laminate for blister pack and blister pack using same |
| JPWO2015194644A1 (en) * | 2014-06-18 | 2017-04-20 | アステラス製薬株式会社 | Blister pack laminate and blister pack using the same |
| JPWO2016063987A1 (en) * | 2014-10-23 | 2017-08-03 | 共同印刷株式会社 | Blister pack laminate, blister pack using the same, blister pack package, and method for producing the laminate |
| WO2016063987A1 (en) * | 2014-10-23 | 2016-04-28 | 共同印刷株式会社 | Laminate for blister pack, blister pack using same, blister pack package, and method for manufacturing same |
| CN107074419B (en) * | 2014-10-23 | 2019-11-05 | 共同印刷株式会社 | Blister package and its package body, blister package laminated body and preparation method thereof |
| CN107074419A (en) * | 2014-10-23 | 2017-08-18 | 共同印刷株式会社 | The manufacture method of blister package layered product, the blister package using it and blister package package body and the layered product |
| JPWO2016204292A1 (en) * | 2015-06-18 | 2018-01-25 | 共同印刷株式会社 | Blister pack laminate and blister pack using the same |
| WO2016204291A1 (en) * | 2015-06-18 | 2016-12-22 | 共同印刷株式会社 | Laminate for use in blister pack, and blister pack using same |
| JPWO2016204291A1 (en) * | 2015-06-18 | 2018-01-25 | 共同印刷株式会社 | Blister pack laminate and blister pack using the same |
| CN107735251A (en) * | 2015-06-18 | 2018-02-23 | 共同印刷株式会社 | Laminate for blister packaging and blister packaging using the same |
| WO2016204293A1 (en) * | 2015-06-18 | 2016-12-22 | 共同印刷株式会社 | Laminate for use in blister pack, and blister pack using same |
| JPWO2016204293A1 (en) * | 2015-06-18 | 2018-01-25 | 共同印刷株式会社 | Blister pack laminate and blister pack using the same |
| WO2016204292A1 (en) * | 2015-06-18 | 2016-12-22 | 共同印刷株式会社 | Laminate for use in blister pack, and blister pack using same |
| WO2019111960A1 (en) * | 2017-12-06 | 2019-06-13 | 大原薬品工業株式会社 | Amorphous-solifenacin drug package |
| JP2020157559A (en) * | 2019-03-26 | 2020-10-01 | 大日本印刷株式会社 | Deodorant laminate |
| JP7255278B2 (en) | 2019-03-26 | 2023-04-11 | 大日本印刷株式会社 | deodorant laminate |
| JP2022062541A (en) * | 2020-10-08 | 2022-04-20 | 共同印刷株式会社 | Transparent moisture-absorbing film |
| JP7607429B2 (en) | 2020-10-08 | 2024-12-27 | 共同印刷株式会社 | Transparent moisture absorbing film |
| JP2022092786A (en) * | 2020-12-11 | 2022-06-23 | 株式会社メタルカラー | Aluminum foil laminate for ptp packaging |
| JP7586478B2 (en) | 2020-12-11 | 2024-11-19 | 株式会社メタルカラー | Aluminum foil laminate for PTP packaging |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2012029899A1 (en) | 2013-10-31 |
| US20130153459A1 (en) | 2013-06-20 |
| EP2612827A4 (en) | 2014-10-22 |
| JP5936542B2 (en) | 2016-06-22 |
| EP2612827A1 (en) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5936542B2 (en) | Package | |
| JP5340925B2 (en) | Pharmaceutical package | |
| JP5241503B2 (en) | Packaging material | |
| US20050220865A1 (en) | Compressed composition comprising magnesium salt | |
| JP6283316B2 (en) | Anagliptin-containing solid preparation | |
| JP5190159B1 (en) | Medicine | |
| JP2006511543A (en) | Stable topiramate formulation | |
| JP5500164B2 (en) | Package of solid preparation | |
| WO2016114017A1 (en) | Film-coated tablets containing olmesartan medoxomil | |
| WO2014112531A1 (en) | Package for solid preparation including 5-hydroxy-1h-imidazole-4-carboxamide or salt or hydrate thereof | |
| JP7252592B2 (en) | packaging material | |
| JP2016222714A (en) | Medicine | |
| JP2013224285A (en) | Pharmaceutical | |
| JP2014034574A (en) | Medicine | |
| KR101125087B1 (en) | Durg package | |
| JP2024023047A (en) | Vildagliptin-containing medicines | |
| JP2025101742A (en) | Selexipag-containing medicines | |
| JP2018062524A (en) | Medicine | |
| JP2017081830A (en) | Solid preparation packages and odor removal method of solid preparations | |
| JP2016124871A (en) | Olmesartan medoxomil-containing tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11821914 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2012531957 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13819133 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REEP | Request for entry into the european phase |
Ref document number: 2011821914 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011821914 Country of ref document: EP |